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CHAPTER I
INTRODUCTION

Major neurological disorders that afflict humans include Alzheimer's disease,
Parkinson's disease, Huntington's chorea, mood disorders and schizophrenia.
Although each of these diseases has distinctive symptoms which allow for ultimate
diagnosis, there is also a certain degree of similarity among the clinical manifestations.
All of these disorders are characterized by cognitive impairments, abnormal movements,
psychoses, and depression that are expressed with varying prevalence and severity in
individual patients (for review see, Heimer et al., 1991). In fact, two of these diseases,
Alzheimer's disease and Parkinson's disease, are often diagnosed within the same
patient (Boller, 1985; Jellinger, 1987; Quinn et al., 1986). This has led to the theory
that these two disorders may be part of a disease continuum, where each "pure" disease
state forms the boundaries, and combinations of symptoms represent the remainder of
the spectrum (Appel, 1981; Korczyn et al., 1986).
The pathology of both Parkinson's disease and Alzheimer's disease involve the
loss of neurons that are located within discrete brain regions and contain specific
neurotransmitters. In Parkinson's disease, abnormalities of the dopaminergic (i.e.
dopamine (DA) containing) system that originates within the midbrain are observed with
the concomitant loss 60 to 85% of the substantia nigra neurons (for review see Boller,
1985; Jellinger, 1986). Clinical signs of Parkinson's disease include: resting tremor,
rigidity and the impaired ability to initiate and execute voluntary movement (Cote and
Crutcher, 1985). In Alzheimer's disease, which accounts for about 70% of all cases of
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dementia or progressive decline of mental function (Cote, 1985), cell loss is the most
dramatic among the cholinergic (acetylcholine-containing) neurons (Cote, 1985;
Lehericy et al., 1991).
The majority of cholinergic neurons affected by Alzheimer's disease are located
at the base of the forebrain in the nucleus basalis of Meynert (Whitehouse et al., 1981 ).
Parkinson's patients can also demonstrate cognitive impairments and dementia
associated with loss of forebrain cholinergic neurons (Boller, 1980; Candy et al., 1983;
Whitehouse, 1986; Whitehouse et al., 1983); and Alzheimer's patients can also present
with rigidity and impaired movement related to loss of dopaminergic neurons (Boller,
1985; Jellinger, 1987; Mayeux and Stem, 1986; Uchihara et al., 1992). This overlap in
clinical manifestations suggests that there may be some strategically located anatomical
systems mediating the cognitive and motoric behaviors that have become deficient in
these disease states.
As a basis for understanding the clinical findings of the aforementioned
neurological diseases, many studies have emphasized the importance of an integrative
knowledge of the normal anatomical connections of the brain regions affected by these
diseases, as well as the functional significance of these innervations. One potential
locus for dysfunction that is similar among these diseases is the basal nucleus of
Meynert or substantia innominata, and also may involve the midbrain dopaminergic
system (for review see, Heimer et al., 1991). Parkinson's disease and Alzheimer's
disease, as well as animal models of these disease states, also demonstrate alterations in
the density of specific DA receptor subtypes (Cortes et al., 1988; Gagnon et al., 1990;
Graham et al., 1990; Seeman et al., 1987). This dissertation is based upon the
hypothesis that the output (measured as changes in neuronal firing rate) of the rat brain
region comparable to the human nucleus basalis of Meynert, the ventral pallidum and the
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adjacent substantia innominata (VP/SI), is altered by DA and dopaminergic agents acting
through specific receptor subtypes.
Recent molecular biological studies have revealed that at least four DA receptor
subtypes exist in the rat brain (Civelli et al., 1991), and possibly five receptors in the
human brain (Grandy et al., 1991). Previously, DA was considered to act through two
receptor subtypes, the Di and the D1 subtype (Kebabian and Caine, 1979).

Both

receptor subtypes have been identified within the VP/SI, and either the Dt or the Di
receptor can mediate the actions of DA applied within the VP/SI. The effect of separate
activation of these receptors by selective agonists on VP/SI firing rate has not been
previously determined. Furthermore, DA may also act as neuromodulator, altering the
effects of other afferent systems on neuronal activity of VP/SI, similar to its action in
other dopaminoceptive brain regions (Graybiel, 1990; Le Moal and Simon, 1991; Yim
and Mogenson, 1982, 1983). The distribution and functional relevance of the other DA
receptor subtypes await future studies with receptor subtype specific dopaminergic
agents.

The hypotheses of this dissertation are:

1)

that the D1 and the Dz

DA receptor subtypes mediate DA-induced effects on VP/SI neuronal
activity. and 2) that DA is a neuromodulatory transmitter within the
VP/SI alterina: neuronal activity evoked in this brain rea:ion by electrical
stimulation of afferents from the amy1:daloid nuclei CAMN>. To investigate
these hypotheses, the following specific aims were proposed:

Specific Aim 1:
mediate

the

To characterize the DA receptor subtypes that

responses

of

single

VP/SI

neurons

to

systemic

administration of DA agonists.
In vivo electrophysiological experiments were performed on anesthetized rats.
Spontaneously active VP/SI neurons were characterized by their action potential
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properties (configuration, amplitude and duration) and activity (firing rate and pattern).
Agonists that selectively activate Di or Di DA receptor subtypes were injected
intravenously in increasing doses. VP/SI neuronal activity was measured by alterations
in firing rate in response to increasing concentrations of DA agonists. If any significant

rate changes occurred, the antagonist specific for the activated receptor subtype was
administered to determine if the rate alterations were mediated by that specific receptor
subtype. To determine whether activation of one receptor subtype was sufficient to
mediate the actions of a nonselective DA agonist (i.e., one that mimics the actions of
endogenous DA within the brain), the combined Di and Di DA agonist apomorphine
was administered, and any effects induced were tested for receptor subtype specificity
by administration of selective D1 or Di antagonists.

Specific Aim 2:

To determine the DA receptor subtypes involved

in the VP/SI responses evoked by endogenously-released DA during
stimulation of midbrain dopaminergic regions. To characterize the VP/SI
responses evoked by electrical activation of the AMN.

To determine if

endogenously-released, and exogenously-applied DA within the VP/SI
modulate AMN-evoked responses of VP/SI neurons.
In vivo electrophysiological experiments were used to describe the effects of
orthodromic (i.e., trans-synaptic) stimulation of the AMN and two midbrain
dopaminergic regions, the ventral tegmental area and the substantia nigra pars compacta
(VTAfSNc), on the activity of VP/SI neurons. To verify whether VTAfSNc stimulation
results in the release of DA in the VP/SI the following criteria were used:

1)

exogenously-applied DA via microiontophoresis should mimic the effects of electrical
stimulation and 2) exogenously-applied Di and/or Di DA antagonists within the VP/SI
should attenuate the effects of VTAfSNc stimulation on VP/SI neuronal firing rate. The
effects of microiontophoretic application of DA agonists selective for the Di or Di
4

receptor subtypes were also assessed to determine the contribution of these subtypes to
alterations of spontaneous activity of VP/SI neurons. In addition, possible modulatory
effects of DA within the VP/SI on VP/SI responses evoked by AMN stimulation were
examined to determine: 1) if electrical stimulation of the VTA/SNc (which prestimabl y
releases endogenous DA), prior to AMN stimulation alters the effects of AMN
stimulation alone; and 2) if exogenous application of DA mimics the modulatory effects
of endogenously-released DA on VP/SI neuronal activity evoked by AMN stimulation.
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CHAYfER II
REVIE\V OF RELATED LITERATURE

In Chapter I, the degeneration of the nucleus basalis of Meynert (or its rat
analogue, the ventral pallidal/substantia innominata region; VP/SI) and the midbrain
dopaminergic regions was described in relation to Alzheimer's disease and Parkinson's
disease. The importance of understanding the normal anatomy and physiology of these
systems was indicated as the foundation for this dissertation. Thus, to illustrate the
relationship of dopamine (DA) to changes in neuronal activity of the VP/SI, this chapter
is divided into three major subdivisions.
Initially, the Anatomy of the Ventral PallidumfSubstantia Innominata
is described to identify the location of the VP/SI within the rat brain; the nomenclature
used for this region is also described. An outline of the afferents to VP/SI is included,
emphasizing the innervation from the amygdala and the midbrain dopaminergic regions,
to provide the anatomical background for the electrophysiological studies in the
following chapters. The anatomy of VP/SI efferents is summarized to suggest the
potential consequences of altering the activity of the VP/SI neurons. In the second
subdivision, Dopamine Receptor Pharmacolo&y, the characteristics of the DA
receptor subtypes (i.e., the Di and D2 DA receptors) are described in relationship to the
effects of specific agonists and antagonists, and their location within the basal forebrain
is also detailed.

The final subdivision, Neurochemical. Behavioral and

Electrophysiolo&ical Studies Involvin& Dopamine, summarizes the known
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interactions between D1 and D2 receptor stimulation, and describes the potential
relevance of these receptors for DA agonist-mediated effects on VP/SI output.
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Anatomy of the Ventral Pallidum/Substantia Innominata

1.ntroduction
The term "ventral pallidum" (VP) was first used by Heimer and Wilson ( 1975)
to describe the rostroventral extension of the globus pallidus beneath the anterior
commissure. The VP displays similar cell morphology to the dorsal globus pallidus
(GP), and in fact is indistinguishable from the GP in Nissl-stained material (Nauta and
Domesick, 1984). However, the VP can be differentiated from the GP by other
histochemical methods, since the VP exhibits a dense plexus of substance P-positive
striatopallidal fibers which readily demarcate it from the GP (Haber and Nauta, 1983;
Heimer et al., 1985). The identification of the VP has redefined the region ventral to the
anterior commissure since the VP was previously considered the subcommissural part
of the substantia innominata (SI; Switzer III et al., 1982).
The SI is restricted to the caudal sublenticular gray (Alheid and Heimer, 1988;
Heimer et al., 1985), "a homogenous region underneath the caudal part of the globus
pallidus" (Switzer III et al., 1982). It is located medial to the caudal aspects of VP
(Paxinos and Watson, 1986). Although anatomically distinct, the SI and VP regions
exhibit similar afferent innervation (Haring and Wang, 1986), terminal configuration
(Grove, 1988a) and electrophysiological characteristics (Napier et al., 199lb). The
cholinergic neurons contained within both regions receive midbrain dopaminergic and
amygdaloid afferents (see review below). Furthermore, the cholinergic neurons of the
VP (Zaborszky and Leranth, 1985) and the SI (Carlsen, 1985) both project to the
basolateral nucleus of the amygdala. Recent anatomical evidence suggests that portions
of the SI may form a continuum with the bed nucleus of the stria terminalis and the
centromedial amygdaloid nuclei, which together are termed "the extended amygdala"
(Alheid and Heimer, 1988). However, the former term of SI is maintained throughout
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the following chapters since functional differences (i.e., action potential duration, firing
rate or pattern) were not observed between SI and VP neuronal populations.

Neuronal Population of the VPISI
The VP/SI is a heterogeneous cell population similar in composition to the GP,
which is primarily comprised of diffusely arranged, large triangular cells with long
radiating dendrites covered with extensive synaptic terminals. Scattered among this cell
population are fewer small cells (Heimer et al., 1985; Heimer and Wilson, 1975).
Immunocytochemical studies of the neurotransmitter content of VP/SI neurons indicates
that the large cell types are either cholinergic or GABAergic (Carlsen et al., 1985;
Kimura et al., 1981; z.aborszky and Leranth, 1985; z.aborszky et al., 1985). The
cholinergic neurons within the VP/SI constitute part of the rat brain region comparable
to the primate nucleus basalis of Meynert (Ch4 cholinergic cell group), and project
widely throughout the cortex and amygdala (for review see, Mesulam et al., 1983a;
Zaborszky et al., 1991).

Afferents of the VPISI
Amy2daloid Afferents. The VP/SI regions in the monkey and the rat are
innervated by amygdalofugal fibers originating from many amygdaloid nuclei (AMN;
Fig. 1; Aggleton et al., 1987; Fuller et al., 1987; Haring and Wang, 1986; Kelley et al.,
1982; Krettek and Price, 1978; Price, 1986; Russchen et al., 1985). The majority of
this AMN projection in the monkey arises from the parvicellular basal nucleus (or
posterior basolateral nucleus; Aggleton et al., 1987; Price, 1986), magnocellular
accessory basal nucleus (or basal medial) and the central nucleus (Price, 1986). Using
retrograde transport of wheat germ agglutinin conjugated to horseradish peroxidase
(WGA-HRP) and anterograde axonal transport of Phaseolus vulgaris
9

Fig. 1. SCHEMATIC ILLUSTRATION OF THE RELA Tl ON SHIP BETWEEN
VP/SI AFFERENT AND EFFERENT PATHWAYS. The VP/SI receives excitatory
(plus symbol) input from the AMN, both inhibitory (minus symbol) and excitatory
inputs from the NA and from the midbrain dopaminergic regions. VP/SI neurons
innervate the cortex (CTX), the AMN, the mediodorsal nucleus of the thalamus (MD thal) and the pedunculopontine nucleus (PPN). Biochemical and molecular studies
suggest that D1 receptors (filled circles) and~ receptors (filled squares) are located on
pre- and postsynaptic membranes of the VP/SI (and the NA). Figure is not drawn to
scale, and, for clarity, all inputs are not shown. ACh - acetylcholine; Asp - Aspartate;
DA - dopamine; ENK - enkephalin; GABA - gamma-aminobutyric acid; Glu - glutamate;
RRF - retrorubral field; SNc - substantia nigra, pars compacta; SP - substance P; VTA ventral tegmental area.
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leucoagglutinin (PHA-L), Grove (1988b) observed similar AMN projections to the
VP/SI in the rat. HRP injections into the rat basolateral nucleus of the amygdala (blA)
anterogradely label VP/SI neurons, some of which are immunoreactive for the enzyme
that synthesizes acetylcholine, choline acetyltransferase (ChAT; Zaborszky et al.,
1984,1991). In addition, some of the AMN afferents to the VP/SI are thought to be
glutamatergic and/or aspartergic, since [3H]D-aspartate and.WGA-HRP injections into
the VP/SI retrogradely label neurons within the AMN (Fig. 1; Fuller et al., 1987).
Thus, some of the AMN afferents are excitatory and innervate both cholinergic and
noncholinergic neurons of the VP/SI.

Midbrain Dopamineriic Afferents. Recent anatomical evidence indicates
that the VP/SI is innervated by midbrain dopaminergic neurons. Catecholaminergic
innervation to the VP/SI in the rat and the monkey originates primarily from the
substantia nigra pars compacta (SNc; Fig. 1; Fallon and Moore, 1978; Haring and
Wang, 1986; Jones and Cuello, 1989; Martinez-Murillo et al., 1988b; Russchen et al.,
1985; Semba et al., 1988; Zaborszky, 1989; Zaborszky et al., 1991), ventral tegmental
area (VTA; Fig. 1; Grove, 1988b; Haring and Wang, 1986; Jones and Cuello, 1989;
Russchen et al., 1985; Semba et al., 1988; Zaborszky, 1989; Zaborszky et al., 1991)
and the retrorubral field (Fig. 1; Deutch et al., 1988; Jimenez-Castellanos and Graybiel,
1987; Jones and Cuello, 1989; Zaborszky, 1989; Zaborszky et al., 1991). The
presence of immunoreactivity against the rate-limiting enzyme for catecholamine
synthesis, tyrosine hydroxylase (TH) in VTA and SNc (Semba et al., 1988), as well as
retrorubral projections to the VP/SI (Deutch et al., 1988) indicates that these afferents
are catecholaminergic, and are likely dopaminergic based on the origin of the
projections. Finally, Voom et al. (1986), used antibodies against DA to demonstrate
that "a dense plexus of thin, varicose dopaminergic fibers" is present in the VP/SI,
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suggesting that this region is a target of these DA antibody-labeled fibers. Thus,
dopaminergic afferents originating from the VTA, the SNc, and the retrorubral field
innervate neurons within the VP/SI.
The dopaminergic region of the midbrain also innervates in particular the
cholinergic subpopulation of VP/SI neurons. Retrograde and anterograde tracing studies
using WGA-HRP and PHA-L, respectively, demonstrate that VTA afferents
occasionally approach individual neurons within the cholinergic-rich regions of the SI
(Grove, 1988b). TH-immunoreactive cell fibers from the VTA, SNc and the retrorubral
field are located near ChAT-immunoreactive VP/SI somata (Jones and Cuello, 1989;
Martinez-Murillo et al., 1988b; for review see, Zaborszky, 1989; Zaborszky et al.,
1991). Further studies using electron microscopy indicate that Ill-containing terminals
contact ChAT-positive neurons in the rat VP/SI (Zaborszky et al., 1992). These
observations suggest that ascending dopaminergic fibers of SNc, VTA and retrorubral
field synapse on cholinergic neurons in VP/SI. In addition, lesions of the ascending
catecholaminergic bundles produced by the toxin, 6-hydroxydopamine (6-0H-DA)
result in reductions of ChAT levels in the VP/SI (Zaborszky et al., 1992). Thus, the
midbrain dopaminergic innervation of cholinergic neurons within the VP/SI may
modulate the activity of these cholinergic neurons.

Other Afferents. The nucleus accumbens (NA) and the remainder of the
ventral striatum provide the most extensive innervation of the VP/SI in the rat and the
monkey (Fig. 1; Grove, 1988b; Haber et al., 1990; Heimer and Wilson, 1975;
Mogenson et al., 1983; Nauta et al., 1978; Walaas and Ouimet, 1989; for review also

see, Heimer and Alheid, 1991; Heimer et al., 1991; Parent, 1990; z.aborszky et al.,
1991). The NA innervation of the VP/SI is topographically distributed such that "core"
and "shell" regions of the NA project to dorsolateral and ventromedial VP/SI,
12

respectively (Zahm and Heimer, 1990). In addition, NA nerve terminals to VP/SI
cholinergic and non-cholinergic neurons presumably contain the inhibitory
neurotransmitters GABA and enkephalin, as well as the excitatory neurotransmitter
substance P (Fig. 1; Bolam et al., 1986; Martinez-Murillo et al., 1988a; Wood and
McQuade, 1986; Zaborszky et al., 1986).
The cortical innervation of the VP/SI originates from the medial prefrontal,
insular, perirhinal and entorhinal cortices in the rat (Grove, 1988b). In the monkey,
projections from the orbitofrontal, insular and temporal cortices project to cholinergic
and non-cholinergic neurons of the VP/SI (Mesulam and Mufson, 1984; Russchen et

al., 1985).
The non-telencephalic inputs to the rat and monkey VP/SI include the
pedunculopontine nucleus (Russchen et al., 1985), the dorsal raphe (Grove, 1988b;
Russchen et al., 1985), the locus ceruleus (Russchen et al., 1985), much of the
hypothalamic and midline thalamic nuclei (Groenewegen and Berendse, 1990; Grove,
1988b; Russchen et al., 1985), the subthalamic nucleus (Groenewegen and Berendse,
1990), the parabrachial nucleus (Bernard et al., 1991; Grove, 1988b; Russchen et al.,
1985), and the nucleus of the solitary tract (Grove, 1988b; Russchen et al., 1985).
Similarly, VP/SI cholinergic neurons are innervated by the dorsal raphe nucleus (Grove,
1988b), and hypothalamus (Grove, 1988b; Mesulam and Mufson, 1984), as well as
noradrenergic neurons from the locus ceruleus (Chang, 1989; Zaborszky et al., 1992).
Thus, these afferents convey multifarious information that may regulate the final output
of the VP/SI to its efferent targets.
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Efferents from the YP/SI
Efferents to the Amygdala. Basal forebrain efferents, including those from
the VP/SI, to the AMN (Fig. 1; Aggleton et al., 1980, 1987; Carlsen et al., 1985; De
Olmos et al., 1985; Emson et al., 1979; Grove, 1988a; Haber et al., 1985; Koliatsos et

al., 1988; Mesulam et al., 1983a; Nagai et al., 1982; Nauta and Domesick, 1984;
Troiano and Siegel, 1978; Woolf and Butcher, 1982; Z.aborszky et al., 1986; Z.aborszky
and Leranth, 1985) arise from both cholinergic and noncholinergic neurons (Carlsen et

al., 1985; Woolf et al., 1986; Z.aborszky and Leranth, 1985). Combined retrograde
transport and ChA T histochemical studies demonstrate that cholinergic projections to the
basolateral amygdala (blA) originate predominantly from the dorsal subcommissural part
of the VP (Z.aborszky and Leranth, 1985) and the sublenticular SI (Carlsen et al.,
1985).

Non-cholinergic neurons from the same region of the VP constitute

approximately 25% of VP/SI efferents projecting to blA (Carlsen et al., 1985). Thus, a
substantial portion of the cholinergic efferents to the AMN is from the VP/SI (Aggleton

et al., 1987; Kitt et al., 1987; Mesulam et al., 1983a, 1983b; Russchen et al., 1985),
and the main target of these efferents in the AMN is the blA (Aggleton et al., 1987;
Carlsen et al., 1985; Haber et al., 1985; Kordower et al., 1989; Otterson, 1980; Woolf
and Butcher, 1982; Woolf et al., 1984; Z.aborszky et al., 1986; for review see, Carlsen,
1989). Additionally, the blA contains more radioactive label for both AChE and ChAT
than any other amygdaloid nucleus tested (Emson et al., 1979). Since few cholinergic
cell bodies have been found in the AMN (Carlsen, 1989; Carlsen and Heimer, 1986;
Kimura et al., 1981), and knife cuts of the ventral pathway that connects the VP/SI with
the AMN produce large depletions of ChATactivity in the AMN (Emson et al., 1979), it
is considered to be cholinoceptive (Amaral and Bassett, 1989; Kimura et al., 1981;
Nagai et al., 1982). There appears to be reciprocal innervation between blA neurons
and VP/SI neurons.
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Qther Telencephalic Efferents. The VP/SI projections to the hippocampus
(Aggleton et al., 1987; Amaral and Cowan, 1980; DeVito, 1980; Koliatsos et al., 1988;
Woolf et al., 1984) are in part cholinergic (Woolf et al., 1984). Similarly, the cortical
mantle receives innervation from neurons within the VP/SI (Fig. 1; Divac, 1975; Haber

et al., 1985), 80-903 of which are cholinergic (Ch4; Rye et al., 1984). In fact, the
VP/SI provides a major source of the cholinergic innervation of the rat, monkey, as well
as human neocortices (Big! et al., 1982; Grove, 1988a; Koliatsos et al., 1988; Lehmann

et al., 1980; Mesulam and Geula, 1988; Mesulam et al., 1983a; Stewart et al., 1985;
Switzer III et al., 1982; Woolf et al., 1983, 1984).
Non-cortical, telencephalic projections from the VP/SI include a reciprocal
innervation to the NA and the remainder of the ventral striatum. In contrast to the
substantial afferent innervation of the VP/SI from the NA and the remainder of the
ventral striatum, the VP/SI provide only minor efferent projections to these regions
(Haber et al., 1985; Spooren et al., 1991b; Woolf et al., 1984).

Non-telencephalic Efferents.

The medial dorsal nucleus of the thalamus

of the rat and monkey receives VP/SI efferents (Fig. 1; Grove, 1988a; Haber et al.,
1985; Hreib et al., 1988; Mogenson et al., 1987; Nauta and Domesick, 1984; Young et

al., 1984), as does the subthalamic nucleus (Canteras et al., 1990; Groenewegen and
Berendse, 1990; Haber et al., 1985; Zahm, 1989) and the zona incerta (Mogenson et
al., 1985). There is also evidence for diencephalic projections from the VP/SI to the

lateral habenular nucleus (Haber et al., 1985; Nauta and Domesick, 1984), and to the
reticular nucleus of the thalamus (Grove, 1988a; Heimer et al., 1985; Jourdain et al.,
1989; Levey et al., 1987), approximately 203 of these VP/SI neurons are ChAT-
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pasitive (Jourdain et al., 1989). Thus, most of the descending efferents of the VP/SI
appear to arise primarily from noncholinergic cells (Grove, 1988a).
The SNc (Grove, 1988a; Haber et al., 1985; 2'.ahm, 1989) and the VTA (Grove,
1988a; Haber et al., 1985; Nauta and Domesick, 1984; Zahm, 1989) receive VP/SI
efferents which suggests reciprocal connections between the VP/SI and these regions.
The pedunculopontine nucleus (Fig. 1; Semba et al., 1989), which includes the
mesencephalic locomotor region (Mogenson et al., 1985; Mogenson and Wu, 1986),
and the hypothalamus (Grove, 1988a; Haber et al., 1985) also receive VP/SI efferents.
Through the cortical and the NA, the AMN, and midbrain dopaminergic afferent
innervations of the VP/SI (Fig. 1), the VP/SI may receive information concerned with
cognitive (for review see Richardson and DeLong, 1988; Salamone, 1986),
motivational (for review see Richardson and DeLong, 1991), and motoric behaviors
(for review see Heimer et al., 1982; Kalivas et al., 1991; Mogenson and Yang, 1991),
respectively. In tum, the efferent connections of the VP/SI to the cortex, the AMN, the
mediodorsal thalamic and pedunculopontine nuclei (Fig. 1), and the hypothalamus
suggest that the VP/SI may be able to influence activity of brain regions concerned with
cognition (Pirch et al., 1986, 1991), motor behavior (for review see Mogenson and
Yang, 1991), motivation (Richardson and Del...ong, 1991), and possibly even visceral
function (Grove, 1988; Haber et al., 1985) . In summary, the VP/SI is located such
that it can convey the output of "limbic antecedents not only into extrapyramidal circuits
but also back into the circuitry of the limbic system" (Haber et al., 1985).
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Dopamine Receptor Pharmacolo2y

Introduction
Multiple subtypes of the DA receptor have been described (for review see,
Civelli et al., 1991; Clark and White, 1987). The generally accepted classification, that
was used for this dissertation is into two subtypes designated Di and D1 (Kebabian and
Calne, 1979; Stoof and Kebabian, 1981). This classification is based upon differences
in the biochemical (Kebabian and Calne, 1979), pharmacological (Billard et al., 1984;
Creese et al., 1983; Stoof and Kebabian, 1984), anatomical (Creese et al., 1983), and
behavioral (Amt, 1985; Barone et al., 1986) profiles of these receptor subtypes. In
addition, the Di and Di receptors are deemed distinct entities since they can be separated
using biochemical techniques (Dumbrille-Ross et al., 1985), and have different DNA
and protein sequences (Civelli et al., 1991). The original classification was based upon
the differential manner by which these subtypes affect the activation of adenylyl cyclase
(ACy). The Di receptor subtype stimulates (Hyttel, 1978; Kebabian and Calne, 1979)
and the Di receptor subtype inhibits (Battaglia et al., 1985; Onali et al., 1984; Stoof and
Kebabian, 1981) the production of cyclic AMP by ACy. The classification was refined
to include later findings that some Di receptors were not linked to this enzyme (Memo et

al., 1986b; Stoof and Kebabian, 1982; Stoof and Verheijden, 1986), and that agonistmediated effects at these

Di receptors are independent of ACy inhibition (Memo et al.,

1986a). These functional studies, combined with the results of radioligand binding
studies, provide a means for assessing the apparent selectivity of agonists and
antagonists that interact with either Di or Di receptor subtypes.
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.Identification of D1 and D2 DA A1:onists and Anta2onists
Tue non-selective and D1 or D2 selective agonists and antagonists used in the
experiments for this dissertation are described below. The D1 DA receptor agonist and
antagonist, used throughout these studies, were SKF38393 (SKF) and SCH23390
(SCH), respectively; the Di DA receptor agonist and antagonist were quinpirole (QUIN)
and sulpiride (SUL), respectively. In addition, apomorphine (APO), a non-selective
DA agonist, was tested in experiment 2 (Chapter IV); and a non-selective DA
antagonist, cis-flupentixol (cis-FLU) was tested in experiment 3 (Chapter V).

D1 or D2 Receptor Selectivity of Dopaminer2ic Aients.

The

selectivity of SKF for the D1 receptor is defined by its ability to stimulate ACy in
homogenates of rat caudate, and by its inability to cause emesis, stereotypic behavior or
to inhibit prolactin release, all of which are associated with activation of the Di receptor
(Setler et al., 1978). SKF is considered a partial agonist for the Di receptor since its
efficacy for stimulating DA-sensitive ACy from rat striatum is about 45% of that
observed for DA (Andersen and Jansen, 1990; Battaglia et al., 1986). Similarly, SCH
is considered selective for the D1 receptor based on its failure to induce prolactinemia,
its potent blockade of DA-stimulated ACy, and its weak displacement of [3H]spiperone
bound to D2 receptor sites (Hyttel, 1983; Hyttel, 1984; Iorio et al., 1983; and see
below).
QUIN (Bach et al., 1980) is a relatively selective and potent Di receptor agonist

since it stimulates the Di receptor in the intermediate lobe of the rat pituitary gland (the
pituitary gland serves as a model for D2 receptors), inhibits ACy activity in
homogenates (Tsuruta et al., 1981); the latter effect is attenuated by SUL and other DA
antagonists which compete for the

Di receptor (Tsuruta et al., 1981).

Likewise, SUL

(Spano et al., 1979) is considered a selective Di antagonist since it stimulates prolactin
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release, attenuates the effects of DA agonists on locomotor activity, which mimics the
actions of classical neuroleptic agents, and JX>tently inhibits the binding of non-selective
and selective D1 DA antagonists (O'Connor and Brown, 1982). In contrast to these
selective comJX>unds, the classical DA agonist, APO, is considered to be non-selective
at these two DA receptors since its effects can be mediated through either receptor
subtype, and cis-FLU is a non-selective DA antagonist which binds to both subtypes
with similar affinity (Creese et al., 1983; and see below).

Binding Characteristics of Selective D1

and

D2

Agonists

and

Antagonists
Indirect Binding Assays for Dopaminer&ic Agents. The interaction of
a dopaminergic agent with a receptor can be characterized by assessing its ability to
inhibit the binding of a radioligand. The pharmacological specificity of the D1 or the Di
receptor site is described based on the dissociation constants for a variety of
dopaminergic agents determined from inhibition of the binding of a radioligand. The
equilibrium inhibition constant or Ki of the unlabeled competing dopaminergic agent is
related to the concentration required to inhibit 503 of the binding of a radioligand to the
same site (McGonigle and Molinoff, 1989) . In rat striatum (STR), the ratio of Ki
values for the D1 versus the D1 binding sites (and the relative potency of the
dopaminergic agents for the D1 to the Di site) for SKF is 18 nM: 9300 nM (517 times
greater for D1); for SCH, it is 0.14 nM : 895 nM (6400 times greater for D1); for
QUIN, it is > 5000 nM : 720 nM (> 7 times greater for Di); for SUL, it is > 10,000 nM
: 70 nM (> 143 times greater for Di); for APO, it is 87 nM: 98nM (1.1 times greater for
D1; Andersen and Jansen, 1990); and for cis-FLU, it is 0.32 nM: 0.34 nM (equipotent
for D1 and
[ 3H]SCH

Di) against the in vitro binding of the selective D1 and Di radioligands,

and [3H]spiroperidol, respectively (Andersen, 1988). The results of these
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binding studies demonstrate that SKF is selective for the D1 receptor since it is a more
potent inhibitor of the D1 than the D1 radioligand; QUIN and SUL are selective for the

Dz receptor since they more readily inhibit binding of the Di radioligand; and, APO and
cis-FLU are nonselective since they display about equal inhibitory potency against both
the Di and Di radioligands.
Although SCH may interact with the serotonin2 binding site, the use of [3H]

SCH as an appropriate marker ofD1 binding sites has previously been established since
this compound selectively binds the D1 receptor both in vitro (Andersen et al., 1985;
Billard et al., 1984) and in vivo (Andersen and Gronvald, 1986; Andersen and Nielsen,
1986) with a low equilibrium dissociation constant, or K<i value of about 0.5 nM in the
rat STR (Billard et al., 1984; Hess et al., 1986; Schulz et al., 1985). Although the

affinity of SCH for serotonin2 sites is in the nanomolar range (Bishchoff et al, 1986), it
is 20 times more potent in displacing a nonselective DA radioligand from striatal D1
receptor sites (Hyttel, 1983). Similarly, when administered in vivo, doses of 1.5 mg/kg
of SCH are required to inhibit 503 of [3H]spiperone binding to serotonin (5HT2)
receptors in frontal cortex (Bishchoff et al., 1986); this dose exceeds those required to
inhibit DA-dependent behaviors

(~

0.1 mg/kg; Molloy and Waddington, 1984).

Comparison of pharmacological characteristics of in vitro [3H]SCH and
[3H]spiroperidol binding in the rat STR with in vivo [3H]SCH and [3H]raclopride
binding in the mouse brain indicates that compounds with selectivity in vitro retained
this selectivity in vivo (Andersen, 1988). Similarly, in the monkey, [3H]SCH labels a
homogeneous and saturable high-affinity Dt site (K<i = 0.35 nM; Madras et al., 1988).
Binding potencies for the Di or D1 sites for select dopaminergic drugs are: SKF (125
times greater for Di; SCH (5000 times greater for Di); QUIN(> 3000 times greater for

Di); SUL (2500 times greater for Di); APO (3 times greater for D1); cis-FLU (2 times
greater for Di); DA (1.4 times greater for Di; Madras et al., 1988).
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Hii:.h and Low Affinity States of Dt and D2 Receptors. The D1 and

Dz receptor sites are thought to exist in two interconvertible states exhibiting either high
or low affinity for agonists, and are modulated by a guanine nucleotide-selective
regulatory protein (Urwyler and Markstein, 1986). The high-affinity state can be
converted into the low-affinity state by the addition of a guanine nucleotide. In the
absence of exogenous guanine nucleotide, both receptors have similar high affinities for
DA of about 40 nM (range 9-74 nM), and low affinities for DA of between 2 and 4µM
(Richfield et al., 1989). With the similarities in dissociation rate constants for DA at the
two subtypes, neither receptor will predominate in its binding of endogenous DA, and if
both receptors are found in the same dendritic area of a neuron, both receptors are likely

to bind endogenously released DA (Richfield et al., 1989). However, the D1 receptor
accounts for an average of 783 of the total number of DA receptors in most regions, but
studies indicate that only 203 may be in the high affinity state (Richfield et al., 1989).
The D1 receptor makes up the remaining 223 of the total number of DA receptors; but,
in contrast to the D1 receptor, 80-903 of the D1 receptors may be in high affinity state

in vitro (Richfield et al., 1989). If these differences in affinity states for the D1 and D2
receptors exist in vivo, the proportions may influence the effects of DA and
dopaminergic agents on individual brain regions.

Distribution of D1 and D2 DA Receptors
Location of Dt and D2 Radiolii:.and Bindini:. Sites.

Autoradiographic

studies have aided the localization of D1 and Di DA binding sites in VP/SI (see Fig. 1).
Binding of [3H]SCH and [3H]spiperone in the rat indicates that the Dt and Di receptor
densities in the VP/SI are 689

± 26 fmoVmg

protein and 70

± 14 fmoVmg

protein,

respectively (Richfield et al., 1989). Similarly, autoradiographic studies of cholinergic
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basal forebrain regions in the rat indicate that absolute density of D1 receptors is 440 ±
53 fmol/mg protein in the VP, and 292 ± 51 fmol/mg protein in the SI; whereas D2
receptor densities are 30 ± 5 fmol/mg protein in the VP and 11 ± 3 fmol/mg protein in
the SI (Zilles et al., 1991 ). Compared with other cholinergic basal forebrain regions,
Di receptors exhibit the highest density in the VP (Zilles et al., 1991). In contrast to the
density of D1 receptors, [3H]SUL binding to the Di receptor indicates that the density of
these receptors in the VP/SI is one-tenth that found in the NA; this is about equal to the
amount for the substantia nigra pars reticulata (SNr), and 1/3 of the amount found in the
SNc (Gehlert and Wamsley, 1985). Thus, the autoradiographic and binding studies
concur that the density of the D1 subtype is high in the VP (Contreras et al., 1987;
Dawson et al., 1988; Napier et al., 1991a) and seems to prevail by as much as 10 times
over the Di subtype (Boyson et al., 1986; Geula and Slevin, 1989; Napier et al., 1991a;
Richfield et al., 1989; Richfield et al., 1987; Zilles et al., 1991), and with an even
greater difference in the SI (Zilles et al., 1991 ).

Location of DARPP-32 Antibody-labeled Sites.

Another applicable

technique for visualizing D1 receptors in the brain is through co-localization of
[3H]SCH binding with DARPP-32, which is a DA- and cyclic AMP-regulated
phosphoprotein (Ouimet et al., 1984). This co-localization does not appear to be
coincidental, since stimulation of D1 receptors in vivo in the rat STR by SKF increases
phosphorylation of DARPP-32 (Lewis et al., 1990).

DARPP-32 appears to be

concentrated in a subpopulation of dopaminoceptive neurons, namely those containing
D1 receptors, where it is localized in cell bodies, dendrites, axons, and nerve terminals
(Hemmings Jr and Greengard, 1986; Ouimet et al., 1984; Walaas and Greengard,
1984). Staining for DARPP-32 in the basal forebrain demonstrates that the VP and the
GP display brightly fluorescent fibers and puncta (presumed nerve terminals), but that
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neuronal cell bodies and dendrites are unstained (Ouimet et al., 1984). The distant
groups of DARPP-32-containing cell bodies (e.g., from the NA and STR) are
considered the source of these DARPP-32-Jabeled fibers and nerve terminals in the VP
and GP, respectively (Ouimet et al., 1984). Thus, the presence both of this receptor
and of DARPP-32 within the VP (see Fig. 1) and the GP suggests that Di receptors
may be located presynaptically on afferents to these regions.

Location of D1 and D2 mRNA-labeled Sites. Studies concur that the
VP contains a higher concentration of Di receptors than the GP (Bardo and Hammer,
1991; Beckstead et al., 1988; Boyson et al., 1986; Dawson et al., 1986a, 1986b;
Mansour et al., 1990; Napier et al., 1991a; Richfield et al., 1987; Savasta et al., 1986).
Additional evidence for this DA receptor diversity in the VP versus the GP is provided
by in situ hybridization techniques demonstrating that the apparent density of D1
receptor mRNA within VP is not as great as that observed in the GP (Mansour et al.,
1990). In contrast, Di DA receptor mRNA labels cells in the VP/SI (Fremeau et al.,
1991), whereas no specific hybridization signals were observed in the GP, suggesting
that the Di receptor in the GP may be present on afferent nerve terminals originating in
other brain regions (Fremeau et al., 1991; Mengod et al., 1991; Weiner et al., 1991).
Considering that DARPP-32 labeling of the VP and the GP (see above) indicates that D 1
receptors are located on afferents to these regions, and that Di mRNA labels VP
neuronal cell bodies, the VP may have both pre- and post-synaptic Di receptors (Fig.
1). Moreover, since the VP postsynaptic receptors are not associated with DARPP-32
labeling, they may also be independent of ACy and cyclic AMP generation.
Corroborating this theory are studies on the amygclala that demonstrate DI receptor
binding (Boyson et al., 1986; Dawson et al., 1986) without DA-stimulated ACy
(Dawson et al., 1986b; Kilts et al., 1988; Mailman et al., 1986). Thus, although the
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yp/SI is morphologically similar to the GP (see anatomical description of VP/SI), the
above evidence suggests that these two regions may have distinct responses to DA
receptor activation.
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Neurochemical. Behavioral and Electrophysiolo&ical Studies Involvin&
Dopamine

Introduction
The studies of this dissertation examined whether separate Di or

Di receptor

activation within the VP/SI region is sufficient to alter VP/SI neuronal activity. The
effects of Di/D2 nonselective agonists on the activity of VP/SI neurons were then
compared to the results of selective DA agonists. In an attempt to formulate a model
incorporating all the conceivable effects of selective Di and Di receptor stimulation, the
functional interactions between Di and

Di receptors on the neuronal activity of the

VP/SI are considered below. The potential interaction between these receptors suggest
three possibilities: independent actions of each receptor, oppositional interactions, and
non-oppositional interactions.
The non-oppositional interactions of Di and Di receptor activation may involve
enabling or synergistic actions. Enabling actions suggest that the activation of one
subtype is necessary for drug actions on the other subtype. It is often suggested that
stimulation of the Di receptor subtype by a selective Di agonist "enables" or permits the
activation of the D1 receptor subtype by a D1 selective agonist to produce the same
magnitude of effect as DA or as nonselective dopaminergic agents. The synergistic
actions of Di and

Di receptors imply that the response magnitude is less when either

receptor subtype is activated alone versus the magnitude of concurrent activation of
these receptors.

Potential Effects of D1 and D2 Receptor Activation
Independent Actions. In the STR, SKF has a dose-dependent effect that is
similar to DA or APO on the induction of inositol phosphates (Undie and Friedman,
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990). SCH, but not SUL, blocks this agonist-induced response, whereas QUIN lacks
1
effect on inositol phosphate accumulation (Undie and Friedman, 1990). DA-induced
stimulation of the depolarization-induced release of [3H]GABA from rat slices isolated
from SNr, entopeduncular nucleus, GP, and caudate-putamen is blocked by SCH,
suggesting that DA modulates the release of GABA via the Di receptor (Floran et al.,
1990). In contrast, Dz, but not Di, receptor activation decreases DA release in the NA
and caudate measured by microdialysis in freely-moving rats (Imperato et al., 1988).
Chronic treatment with SCH increases the density of striatal Di receptors, which are
located postsynaptically on intrinsic neurons (Cross and Waddington, 1981; Filloux et

al., 1987; Leff et al., 1981), without altering the Dz receptor population (Creese and
Chen, 1985).
The independent effects of Di or Dz receptor activation likewise are expressed
through specific behavioral responses. Di receptor activation in rats mediates nonstereotyped sniffing (Molloy and Waddington, 1985), and induces episodes of a
specific grooming behavior that involves the snout being directed vigorously into the
body (Dall'Olio et al., 1988; Molloy and Waddington, 1984, 1985; Starr and Starr,

1986). These SKF-induced behaviors are blocked by SCH but not by a Dz antagonist,
suggesting selective activation of Di receptors (Molloy and Waddington, 1984, 1985).
SKF also induces grooming in rats chronically pretreated with SCH (Dall'Olio et al.,

1988). Unilateral injection of SKF into the SNr results in contralateral rotation (Asin
and Montana, 1988; Jackson and Kelly, 1983). Di receptors have been implicated in
the modulation of:

1) rapid eye movement sleep (Trampus et al., 1991), 2) bar

pressing to receive rewarding VTA stimulation (Kurumiya and Nakajima, 1988;
Nakajima and McKenzie, 1986), and 3) the duration of free-running rhythms of
locomotor activity during constant dark conditions (Yamada and Martin-Iverson, 1991)
in the rat.

Mouthing movements that mimic oro-facial dyskinesia are produced

26

following intra-VP/SI injection of SKF, and are attenuated by local injection of SCH
(Spooren et al., 199la). Similarly, injection of SKF82958 (a full Di agonist) within the
VP induces prominent mouthing movements in addition to enhancing locomotion and
rearing/wall climbing behaviors (Napier and Rehman, 1992).

In contrast to Di-mediated effects, Di receptor stimulation has been implicated in
the anti.psychotic and anti-dopaminergic activity of classical neuroleptic agents (Creese et

al., 1976; Ellenbroek et al., 1991). Activation of D1 receptors in rats mediates
locomotion, rotational behavior and some stereotypic sniffing and rearing behavior (for
review see Clark and White, 1987). D1 receptor agonists increase the amplitude, but
not duration, of free-running rhythms of locomotor activity in rats maintained in a
constant dark environment (Yamada and Martin-Iverson, 1991). Intra-NA injections of
QUIN, but not SKF, reduces exploratory locomotion in a dose-dependent manner
(Mogenson and Wu, 1991). QUIN injected within the GP increases locomotion and
rearing/wall climbing behaviors (Napier and Rehman, 1992).
Electrophysiological studies concur that separate Di or Di receptor activation is
sufficient to alter neuronal activity. White and Wang (1986) observed a heterogeneous
population of NA neurons that respond with rate suppression to both Di and D1
agonists, or to either agonist independently. Intrastriatal infusion of SKF, which
mimics the effects of nonselective DA agonists (Groves et al., 1981; Tepper et al.,
1984), decreases the ability of antidromic stimulation to initiate action potentials (i.e.,
application of a Di agonist within the terminal region decreases the excitability of the
terminals to antidromic stimulation). Thus, the terminal excitability of antidromicallyidentified nigrostriatal dopaminergic neurons is attenuated by Di receptor activation
(Diana et al., 1989).

However, D1 receptors are involved with enhancement of

terminal excitability of hippocampal-NA neurons since microiontophoretic application of
DA or QUIN within the NA mimics the effects of VTA stimulation on the excitability of
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these hippocampal terminals (Yang and Mogenson, 1986). In contrast, the excitatory
response of striatal neurons to cortical stimulation is attenuated by electrical stimulation
of the nigrostriatal dopaminergic system via D2 receptors (Vives and Mogenson,
1986b). Signal transmission from the hippocampus to the VP neurons that innervate the
pedunculopontine nucleus is modulated by intra-NA application of QUIN (Yang and
Mogenson, 1987). Thus, the possibility of independent actions of D1 and Di receptor
agonists is supported by neurochemical, behavioral and electrophysiological studies.

Qpposine; Actions of D1 and Di Receptor Activation.

Neurochemical

studies have indicated that D1 receptor agonists stimulate, and Di receptor agonists
inhibit, ACy and cyclic AMP efflux and accumulation within the STR (Kelley and
Nahorski, 1986; Pifl et al., 1991; Setler et al., 1978; Stoof and Verheijden, 1986).
Recent studies reveal that D1 receptors can be positively coupled to phospholipase C,
leading to the production of phosphatidyl inositols and diacyl-glycerol; conversely, Di
receptors are negatively linked to this enzyme (Enjalbert et al., 1986; Pizzi et al., 1988).
SKF also antagonizes Di receptor-mediated inhibition of DA metabolism in vivo in rats
(Saller and Salama, 1985).

Furthermore, activation of the D1 increases, whereas

activation of the Di receptor decreases striatal acetylcholine release (Ajima et al., 1990;
Damsma et al., 1990; Gorell and Czarnecki, 1986; Gorell et al., 1986).
Behavioral and electrophysiological studies substantiate the opposing interaction
of D1 and D2 receptors. The two receptors mediate opposite effects on: 1) oral
movements (Johansson et al., 1987; Koshikawa et al., 1990b; Rosengarten et al.,
1986); 2) the convulsant effects of pilocarpine (Al-Tajir et al., 1990); 3) body
temperature (Costentin et al., 1990); 4) the amount of area traversed during exploratory
behavior (Eilam et al., 1991); and, 5) the direction of rotation following injection of DI
or D2 selective agonists into the SNr (Asin and Montana, 1988; Jackson and Kelly,
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l983) in rats. In addition, atypical jerking response is not induced by the

Di agonist

alone, but is dependent upon the removal of tonic Di-mediated dopaminergic activity
that would otherwise oppose its manifestation (Murray and Waddington, 1989).
Similarly, D1 receptor agonists enhance, whereas D2 receptor agonists suppress eventrelated slow potentials recorded from the rat cortex (Pirch et al., 1988), which are
generated by VP/SI cholinergic neurons (Pirch et al., 1986). Several neurochemical,
behavioral and electrophysiological findings suggest that D1 and Di receptor stimulation
can express opposing influences on certain functions within the brain.

Non-oppositional Interactions between D1 and D2 Receptor
Activation. Neurochemical studies reveal that Di/Di receptor synergism is involved
in: 1) the dopaminergic control of the electrically-evoked release of [3H]GABA in rat
prefrontal cortex (Retaux et al., 1991) and, 2) DA-mediated inhibition of NA+/K+dependent ATPase (Bertorello et al., 1990).
A variety of behaviors also involve the cooperative effects of stimulating D1 and
D1 receptors, and the expression of some behaviors require the activation of both

receptor subtypes (for review see, Clark and White, 1987; Murray and Waddington,
1989; Waddington and O'Boyle, 1989; White et al., 1988). Stimulation of both Di and

Di postsynaptic receptors is necessary for

the expression of stereotyped (Amt et al.,

1987; Braun and Chase, 1986; Vasse et al., 1988), and climbing (Moore and Axton,
1988; Vasse et al., 1988) behaviors. Priming with QUIN is essential for SKF-mediated
effects on contralateral turning in rats with unilateral 6-0H-DA lesions (Morelli et al.,
1990). In monkeys, the D1 receptor has a permissive role in yawning induced by

Di

receptor activation (Code and Tang, 1991). D1 receptor activation can also potentiate Di
receptor-mediated motor responses (Amt et al., 1988; Barone et al., 1986; Molloy et al.,
1988; Molloy and Waddington, 1985; Morelli et al., 1987; Plaznik et al., 1989;
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Robertson and Robertson, 1986, 1987), stereotypies (Bordi and Meller, 1989;
Mashurano and Waddington, 1986; Meller et al., 1988), catalepsy (Dall'Olio et al.,
1988; Wanibuchi and Usuda, 1990), jaw movements (Koshikawa et al., 1989, 1990a),
and yawning (Longoni et al., 1987; Spina et al., 1989) in normal and DA-depleted rats.
Furthermore, the synergistic effects of Di and Dz agonists on rotational behavior may
also be mediated through Di and Dz receptor activation in separate brain regions, such
as the effect of Di receptor agonists in the SNr, and

Dz receptor agonists in the STR

(Robertson and Robertson, 1987).
In electrophysiological studies, synergistic interactions between Di and Dz

receptors: 1) increases the activity of GP neurons (Carlson et al., 1987a; Walters et al.,
1987), 2) potentiates both excitatory and inhibitory effects of SNr neurons as compared
to activation of individual receptor (Weick and Walters, 1987), and, 3) decreases the
activity of NA neurons (White, 1987). In addition, VP neuronal activity is excited
similarly by intra-NA application of DA, or SKF followed by QUIN, but not by either
agonist alone (Yang and Mogenson, 1989). Much of the evidence supporting the
synergistic effects of Di and Dz receptor stimulation originates from studies of the
systemic effects of DA agonists and antagonists, which may simultaneously activate Di
and Dz receptors in many brain regions.

Effects of Endoe,enously-released and Exoe,enously-applied DA
The sensitivity of evoked neuronal activity of several brain regions to DA and
dopaminergic agonists and antagonists has been studied using similar methods to those
proposed in this dissertation. The categorization of DA as either an excitatory or
inhibitory neurotransmitter is controversial since these studies indicate that actions of
DA depend on the brain region examined. Electrophysiologic studies of the welldefined SNc projection to the STR indicate that stimulation of the SNc has an excitatory
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effect on these STR neurons (Frigyesi and Purpura, 1967; Fujimoto et al., 1981; Hull et
al., 1970; Kitai et al., 1975, 1976; Ohno et al., 1985, 1986; York, 1967).

Microiontophoretic application of DA (Ohno et al., 1985, 1986; York, 1967) and DA

Di, but not D1, receptor antagonists within the STR inhibits the excitatory SNc-evoked
response, suggesting that the effects of SNc stimulation on STR neuronal activity is
mediated by DA acting at Di receptors (Ohno et al., 1985, 1986).
However, DA can have an inhibitory role since other studies reveal that
VTNSNc (Connor, 1970; Le Douarin et al., 1986; Zarzecki et al., 1976) or medial
forebrain bundle (Akaoka et al., 1987) stimulation usually evokes inhibitory STR
responses (in 733 and 473 of the neurons tested in Akaoka et al., 1987; Connor,
1970, respectively). The STR neurons with inhibitory responses to VTNSNc (Connor,
1970; Le Douarin et al., 1986; Zarzecki et al., 1976) or medial forebrain bundle
(Akaoka et al., 1987) stimulation also are suppressed by microiontophoretic application
of DA. The complexity of STR responses to SNc stimulation may result from the
extensive innervation of the STR region by dopaminoceptive brain regions that are
concurrently affected by SNc stimulation. Intracellular recording studies supporting this
conclusion reveal that only long latency excitatory postsynaptic potentials (the long
latency time frame is analogous to our short latency response described in Chapter V)
remain after removal of all of the non-nigral response components by denervation of the
cortical, and transection of the thalamic inputs (Wilson et al., 1982).
Stimulation of the sensory motor cortex also produces excitatory responses in
STR neurons that are attenuated by preceding cortical stimulation with train stimulation
of the SNc (Hirata et al., 1984), or intra-STR application of DA (Hirata et al., 1984;
Johnson et al., 1983). Intra-STR application of SUL, but not SCH, reversed the
attenuating effect of SNc stimulation on the excitatory response of STR neurons to
cortical stimulation (Vives and Mogenson, 1986a), suggesting the involvement of Di
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DA receptors in SNc-evoked STR responses to cortical stimulation. Stimulation of the
SNc produced predominantly inhibitory, yet some excitatory affects on the activity of
STR neurons; and microiontophoretic application of DA also inhibits glutamate-induced
excitatory effects of STR neurons (Zarzecki et al., 1977).
Microiontophoretic studies indicate that DA is generally a inhibitory
neurotransmitter when applied locally within the brain. DA inhibits the glutamateinduced firing of the majority of NA neurons tested (Akaike et al., 1983). Excitatory
NA responses to hippocampal or AMN stimulation are attenuated:

1) by prior

stimulation of the VT A with a train of pulses, or 2) by intra-NA application of DA,
indicating that DA mediates the VTA-evoked attenuation of the excitatory NA responses
(Yang and Mogenson, 1984; Yim and Mogenson, 1982). Likewise, excitatory NA
responses to stimulation of the parafascicular nucleus of the thalamus are inhibited by:
1) VTA conditioning stimulation and iontophoretically applied DA (Akaike et al., 1984),
and 2) iontophoretically-applied selective Di or D1 agonists (Hara et al., 1989) within
the NA. In addition, VTA stimulation alters the responses of NA neurons to sensory
input (West and Michael, 1990).
The activity of GP neurons is inhibited by stimulating the sensory motor cortex,
and these inhibitory responses are reduced when the SNc is activated with a train of
pulses prior to cortical stimulation (Hirata and Mogenson, 1984). Stimulation of the
hippocampus (Tsai et al., 1989) or the AMN (Tsai et al., 1989; Yim and Mogenson,
1983) evokes inhibitory and excitatory VP responses. The inhibitory VP responses to
AMN stimulation are attenuated: 1) by DA released within the NA, or 2) by prior
stimulation of the VTA with a train of pulses (Yim and Mogenson, 1983). Thus,
orthodromic stimulation studies provide strong evidence that DA released from the nerve
terminals of the VTA and the SNc produces receptor spe.cific effects on neuronal activity
of several brain regions. In addition, inhibitory actions of VT A/SNc stimulation on the
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neuronal activity of target regions that appear to be modulate the effects of other
afferents, are mimicked by microiontophoretically-applied DA.
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f_unctional Relevance for DA within the VP/SI
Studies indicate that the VP/SI receives dopaminergic innervation from the
midbrain, and that D1 and Di receptors are located within this region (see anatomical
review and distribution of D1 and Di receptors above). Biochemical studies corroborate
this anatomical evidence since DA and its major metabolites have been isolated from
VP/SI tissue, and are significantly reduced following 6-0H-DA lesions of midbrain
dopaminergic regions (Geula and Slevin, 1989; Napier and Potter, 1989). Recent
behavioral studies demonstrate that intracerebral microinjections of DA directly into the
VP/SI dose-dependently increase locomotion in an open field (Napier and Chrobak,
1992; Napier and Rehman, 1992), but do not alter working memory in rats previously
trained on a 12 arm radial maze (Napier and Chrobak, 1992). Pretreatment by systemic
administration of the D1/D2 antagonist, cis-FLU, attenuates the increase in locomotor
activity (Napier and Chrobak, 1992). Intra-VP/SI injection of DA or a D1 agonist,
results in dose-related increases rearing and wall climbing, and the Di agonist also
produced robust mouthing movements (Napier and Rehman, 1992). Similarly, intraVP/SI injection of SKF in cats elicits oro-facial dyskinesia that are attenuated by local
injection of SCH (Spooren et al., 1991a). Thus, intra-VP/SI DA application elicits
readily discernible motoric and grooming behaviors, whereas assessment of cognitive
behaviors await more discrete testing paradigms.
Likewise, electrophysiological studies reveal that VP/SI neurons are affected by:
1) systemic administration of APO, 2) microiontophoretic application of DA (Napier et

al., 199lb) and 3) electrical stimulation of the SNc (Napier et al., 1991a). Systemic
administration of APO often induces dose-dependent rate increases (fewer neurons
demonstrate dose-dependent rate suppressions), that are attenuated by haloperidol,
verifying that the actions of the agonist are mediated through DA receptors (Napier et

al., 199la). Although intra-NA DA application also increases the firing rate of VP/SI
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neurons (Yang and Mogenson, 1989), the excitatory effects of APO remains following
pharmacological inactivation of the NA, indicating that APO-mediated effects on VP/SI
neuronal activity may be independent of the NA (Napier, l 992a). In addition, intraVP/SI application of DA mediates VP/SI rate excitations and inhibitions, with the latter
observed more frequently (Napier et al., 199lb).

Systemic administration of

haloperidol or SCH attenuate these effects, indicating that alterations in activity of VP/SI
neurons involve both D1 and D1 receptors subtypes (Napier et al., 199lb).
Furthermore, preliminary data corroborates the inhibitory effects of DA within the
VP/SI since electrical stimulation of the SNc evokes inhibitory VP/SI responses (Napier

et al., 1991a). Thus, the combined results from neurochemical, behavioral and
electrophysiological studies indicate that DA is not only located within the VP/SI, but is
also functionally relevant in this brain region.
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Summary
This literature review has outlined 1) the afferent and efferent anatomy of the
VP/SI; 2) the pharmacology of Di and
the localization of Di and

Di

Di dopaminergic agents, as well as evidence of

receptor subtypes within the VP/SI; 3) the possible

interactions between Di and D1 receptor activation; and, 4) the functional relevance of

DA within the VP/SI. The hypotheses of this dissertation are:

1)

that the D1

and the Dz DA receptor subtypes mediate DA-induced effects on VP/SI
neuronal activity. and 2l that DA is a neuromodulatory transmitter within
the VP/SI alterine neuronal activity evoked in this brain reeion by
~lectrical

stimulation of afferents from the amyedaloid nuclei (AMNl. To

investigate these hypotheses, the following specific aims were proposed:

Specific Aim 1:
mediate

the

To characterize the DA receptor subtypes that

responses

of

single

VP/SI

neurons

to

systemic

administration of DA agonists.
In vivo electrophysiological experiments were performed on anesthetized rats to
investigate the responsiveness of single VP/SI neurons to systemic administration of the
selective Di agonist, SKF, and the selective D1 agonist, QUIN. Spontaneously active
VP/SI neurons were characterized by action potential properties (configuration,
amplitude and duration) and activity (firing rate and pattern). SKF or QUIN were
injected intravenously in increasing doses. VP/SI neuronal activity was assessed as
alterations in firing rate in response to increasing drug concentrations. If any significant
rate changes occurred, the antagonist specific for the receptor subtype activated (i.e.,
SCH for the Di, and SUL for the

Di receptor)

were injected to determine if the rate

alterations were mediated by specific receptor subtypes. To determine whether
activation of one receptor subtype was sufficient to mediate the actions of a nonselective

DA agonist (i.e., one that mimics the actions of endogenous DA within the brain), the
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Dt and Dz DA agonist apomorphine was administered, and any effects induced were
tested for receptor subtype specificity by administration of selective Di or Dz
antagonists.

Specific Aim 2:

To determine the DA receptor subtypes involved

in the VP/SI responses evoked by endogenously-released DA during
stimulation of midbrain dopaminergic regions. To characterize the VP/SI
responses evoked by electrical activation of the AMN.

To determine if

endogenously-released, and exogenously-applied DA within the VP/SI
modulate AMN-evoked responses of VP/SI neurons.
In vivo electrophysiological experiments were used to describe the effects of
orthodromic (i.e., trans-synaptic) stimulation of the AMN and two midbrain
dopaminergic regions, the ventral tegmental area and the substantia nigra pars compacta
(VTA/SNc), on the activity of VP/SI neurons. To verify whether VTA/SNc stimulation

results in the release of DA in the VP/SI the following criteria were used:

1)

exogenously-applied DA via microiontophoresis should mimic the effects of electrical
stimulation and 2) exogenously-applied SCH and/or SUL within the VP/SI should
attenuate the effects of electrical stimulation on VP/SI neuronal firing rate. The effects
of microiontophoretic application of SKF and QUIN were also assessed to determine
the contribution of these subtypes to alterations of spontaneous activity of VP/SI
neurons. In addition, possible modulatory effects of DA within the VP/SI on VP/SI
responses evoked by AMN stimulation were examined to determine: 1) if electrical
stimulation of the VTA/SNc (which presumably releases endogenous DA), prior to
AMN stimulation alters the effects of AMN stimulation alone, and 2) exogenous
application of DA mimics the modulatory effects of endogenously-released DA on
VP/SI neuronal activity that resulted from AMN stimulation.

37

CHAYfER Ill
Dt AND D2 DOPAMINE AGONISTS INDUCE OPPOSITE CHANGES
IN THE FIRING RATE OF VENTRAL PALLIDAL NEURONS

Abstract

Selective D1 and Dz dopamine (DA) agonists were used to determine the
contributions of each receptor subtype in the modulation of firing rate of ventral
pallidum/substantia innominata (VP/SI) neurons. Administration of cumulative doses of
the Dz agonist, quinpirole (QUIN), decreased activity in 59% of the VP/SI cells tested.
The decrease in firing rate was dose-dependent between 0.002-0.2 mg/kg, i.v. and was
blocked by the Dz antagonist, sulpiride (SUL; 12.5 mg/kg, i.v.). In addition, the
magnitude and the distribution of responses of VP/SI neurons was not changed
following administration of QUIN as a single versus a divided cumulative dose of 0.1
mg/kg.
In contrast, administration of the D1 agonist, SKF38393 (SKF), excited 693 of
the neurons sampled.

Similar maximal responses were observed following

administration of either a single or a divided cumulative dose of 3.2 mg/kg of SKF.
The D1 receptor antagonist, SCH23390 (SCH; 0.1-0.4 mg/kg, i.v.) often attenuated the
SKF-induced increases.
The results illustrate that, 1) VP/SI neurons are sensitive to systemically
administered DA agonists, 2) D1 or D1 receptor activation is sufficient to change the
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activity of these neurons, and 3) these selective agonists mediate opposite effects on
VP/SI neuronal activity. These differential responses contrast with effects observed for
other dopaminoceptive brain regions, and distinguish VP/SI neurons from
morphologically related neurons of the dorsal globus pallidus.

Introduction

Di or Dz DA receptors are classified based upon differential regulation of the
enzyme, adenylate cyclase. Di receptor is coupled positively to adenylate cyclase
(Kebabian and Calne, 1979), and

Dz

receptor is negatively coupled to the enzyme

(Stoof and Kebabian, 1981). The availability of agonists and antagonists selective for
Di or

Dz receptors has provided the

means to investigate the roles of DA receptor

subtypes in the modulation of neuronal systems. Electrophysiologic studies of
dopaminoceptive brain regions, including the striatum (STR), nucleus accumbens (NA),
globus pallidus (GP), and amygdala (AMN), as well as the substantia nigra (SNc) and
ventral tegmental area (VTA), have contributed significantly toward understanding the
role of DA receptor subtypes on neuronal transmission.
Systemically administered selective Dz agonists increase the firing rate of STR
neurons (Hu and Wang, 1988), induce biphasic changes in NA activity (White and
Wang, 1986), suppress SNc neurons innervating the STR (Kelland et al., 1988), and
increase GP neuronal activity (Carlson et al., 1988). The Di selective agonist, SKF
inhibits the firing rate of neurons in the STR (Hu and Wang, 1988) and NA (White and
Wang, 1986). Under similar anesthetic conditions to the above studies, SNc neurons
are not affected by systemic administration of this agonist alone (Carlson et al., 1987b;
Kelland et al., 1988). High doses of SKF often increase GP neuronal activity (Carlson
et al., 1988), but behaviorally relevant doses (Meller et al., 1988; Vasse et al., 1988) are
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not effective. Thus, DA receptor activation results in complex responses that may be
distinctive for the brain region under investigation.
The ventral pallidum/substantia innominata (VP/SI) is a ventral extension of the
GP (Heimer and Wilson, 1975), and is directly contacted by presumptive
catecholaminergic neurons (for review see Zaborszky et al., 1991). DA has been
suggested as a possible neurotransmitter for this input (for review see Napier et al.,
199la). DA and its metabolites are located within VP/SI and lesions of midbrain
dopaminergic neurons yield significant depletion of DA within VP/SI tissue (Napier and
Potter, 1989).

In addition, VP/SI neurons are altered by microiontophoretic

applications of DA, often exhibiting an inhibition of firing rate (Napier and Potter,
1989), but the receptor subtypes involved have not been determined. Autoradiographic
studies demonstrate that the VP/SI contains Di and Di binding sites (Contreras et al.,
1987).
To evaluate the functional consequence of Di and of D1 DA receptor stimulation
on extracellularly recorded single unit activity of VP/SI neurons, the present in vivo
electrophysiologic study characterized effects following systemic administration of the
Di agonist, SKF, and the D1 agonist, QUIN. Because responses to DA agonists differ
among brain regions, initial experiments defined the dose-response relationships of the
effects induced by these agonists in the VP/SI in order to compare among
dopaminoceptive brain regions. Agonists were administered as multiple dose treatments
emulating the protocol and dose range used in previous electrophysiologic studies on
other brain regions (e.g., Carlson et al., 1987b). In a subsequent experiment, agonist
doses that induced near maximal responses were injected as a single dose treatment to
verify that the onset, magnitude, and duration of the effects of VP/SI neurons were
similar to those observed after administration of the agonist in divided doses.
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Material and Methods

.s.urgical freparation of Animals
Male Sprague-Dawley rats (270-350 g, Harlan Inc., Indianapolis, IN) were
anesthetized with chloral hydrate (400 mg/kg, i.p.), and a lateral tail vein was
cannulated for intravenous administration of treatment drugs and supplements of chloral
hydrate. The rats were mounted in a stereotaxic apparatus (David Kopf, Tujunga, CA)
with the nose piece set at 3.3 mm below the horizontal, and the skull was exposed. A
burr hole was drilled in the skull 0.5 mm posterior to Bregma, and ± 2.5 mm lateral to
the midline for recording in the VP/SI (Paxinos and Watson, 1986), and the dura was
removed. During all experiments, body temperature was maintained at 37 °c with a
thermostatically controlled heating pad (Fintronics, Inc., Orange, CT).

Extracellular Recordina:
Neuronal activity was recorded extracellularly through a single barrel
micropipette pulled from 2.0 mm O.D. glass tubing (A-M Systems, Inc., Everett, WA),
with a vertical electrode puller (Narishige PE-2, Tokyo, Japan). The tip was broken
back to a diameter of approximately 2 µm, and the electrode was filled with a 2M
sodium chloride solution saturated with fast green dye (Fisher Scientific Co., St. Louis,
MO). The impedance of these electrodes was 4-8 megohms, measured in vitro at 165

Hz with a micro-electrode tester (Winston Electronics, San Francisco, CA). The
electrode was lowered through the hole with a hydraulic microdrive (Trent Wells, South
Gate, CA), within a VP/SI sampling distance of7.5 - 8.5 mm below the dura.
Electrical signals recorded by the electrode were passed through a highimpedance amplifier (Fintronics, Inc., Orange, CT), filtered, and monitored on an
oscilloscope (Tektronix, Inc., Beaverton, OR) and audiomonitor (Haer Inst., Inc.,
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Brunswick, ME). The signals were relayed to a window discriminator (Fintronics,
Inc.) with the digital output representing action potentials from single, spontaneously
active neurons. The output was recorded by a computer (IBM-AT) that, with the aid of
Brainstorm Systems Spikes to Stats software (Chapel Hill, NC), displayed rate
histograms, and stored all data for future statistical analysis.

Urug Administration
After a 5 min period of stable activity was recorded for each VP/SI neuron,
drugs were administered through the tail vein cannula. Stable baseline activity was
reestablished following any chloral hydrate supplements, and the anesthetic was not
administered during DA agent administration. The specific D2 agonist, QUIN (Tsuruta

et al., 1981; 0.002 - 0.2 or 0.1 - 25.6 mg/kg) or the specific D1 agonist, SKF (Setler et
al., 1978; 0.002 - 1.6 or 0.1 - 25.6 mg/kg) was injected at 2 min intervals such that
each dose added to the previous dose. Control studies were conducted using volumes
of vehicle solutions that were similar to those used to dissolve the agonists. Only one
neuron was recorded from each animal.
The selective D2 antagonist, SUL (O'Connor and Brown, 1982; 12.5 - 25
mg/kg, one neuron was tested also with 50 mg/kg) or the selective D1 antagonist, SCH
(Hyttel, 1983; 0.1 - 0.4 mg/kg) was administered routinely 5 min after the injection of
the highest dose of QUIN or SKF, respectively. Antagonist doses were selected based
on their capacity to block QUIN- and SKF-induced responses observed in other studies
(Hu and Wang, 1988; Molloy and Waddington, 1984).
Single injection treatments of QUIN or SKF were tested to determine if
responses with this protocol were similar to those observed with cumulative dose
administration. For this experiment, baseline firing rate was monitored for 5 min, after
which 0.1 mg/kg of QUIN or 3.2 mg/kg of SKF was administered and neuronal activity
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was monitored for I 0 min. In some studies, firing rate was monitored for an additional
20 min during which two successive antagonist vehicle injections (either tartaric acid or
saline solution) were administered at 10 min intervals after the agonist. These studies
verified that maximal agonist responses could be obtained within 2 min of injection and
were maintained for at least 20 min. For the remaining neurons, SUL, then SCH, was
administered at I 0 min intervals to test for antagonism of the QUIN-induced responses,
and the antagonists were injected in reverse order following SKF.
Neuronal activity following drug injections was converted to a percent of
pretreatment control, determined by comparison of the firing rates averaged over the last

30 s interval of pre-drug baseline (considered as 1003) with that observed during the
last 30 s interval following each injection. This interval was increased for neurons that
exhibited a cyclic firing pattern lasting more than 30 s to accurately assess drug effects.
Treatment rates that differed from pretreatment levels by greater than 203 (and
maintained for at least two consecutive doses in the multiple dose experiments), were
considered significant. Antagonism was defined as an attenuation of agonist-induced
responses by at least 303. A more stringent criterion than that for agonist-induced
responses was select to assess antagonism since most of the antagonist effects exceeded
the usual 203 criterion. Reversal was defined as a re-establishment of pretreatment
rates. The number of neurons that satisfied these criteria for a given response direction
were determined.
At the end of each experiment, the rat was overdosed with chloral hydrate and
the location of the recording site was marked with fast green dye by passing anionic
current for 10 - 30 s through the electrode. The brain was removed, mounted and
frozen, then cut with a microtome to locate the fast green dye deposit. The site of the
fast green deposit that denoted the recording site was recorded on standardized
stereotaxic maps reproduced from Paxinos and Watson (1986).
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s.tatistics
Cumulative log dose-response curves were constructed for the effects of
repeated injections of DA agonists on the firing rate of VP/SI neurons. EDso, defined
as the dose required to induce half of the maximum response, was determined from the
x-axis intercept of the linear portion of each curve using linear regression analysis of a
double reciprocal plot of dose versus population response values. Emax, defined as the
maximal observed effect, standardized as percent of baseline firing rate, was determined
from the y-axis intercept. These data are presented as mean ± standard error of the
mean.
To compare overlapping portions of the dose response curves for low and high
dose administration of QUIN or SKF, a repeated measures analysis of variance
(ANOVA) was used. In the experiment involving single injection treatments of SKF or

QUIN, statistical differences among groups were determined using a repeated measures
ANOV A and Tukey's test; and a

t -

test was used to compare mean rate responses to

agonist administration between single and cumulative dose treatment. Chi-square
analysis was used to detect changes in distribution of responses to the agonists. The
criterion of significance for all statistical tests wasp < 0.05.

Dru2s
The drugs used in this study were chloral hydrate (Sigma Chem. Co., St. Louis,
MO), quinpirole (LY 171555; trans-(-)-4aR-4,4a,5,6,7 ,8,8a,9-octahydro-5-propyl-1H(or 2H)-pyrazolo-(3,4-g) quinoline monohydrochloride; Lilly Res. Lab., Indianapolis,
IN), SCH23390 ((R)-( + )-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-IH-3benzazepin-7-ol hemimaleate; Schering Corp., Bloomfield,NJ), SKF38393 (2,3,4,5tetrahydro-1-phenyl-1H-3-benzazepine-7 ,8-diol hydrochloride; Smith, Kline, and
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French Labs., Philadelphia, PA), and sulpiride (5-(aminosulfonyl)-N-((l-ethyl-2pyrrolidinyl) methyl)-2-methoxybenzamide; Sigma Chem Co.). Chloral hydrate, QUIN
and concentrations of SKF below 3 mg/ml were dissolved in a saline solution. Higher
concentrations of SKF were dissolved in water. SCH was dissolved in a 0.33 tartaric
acid solution, and SUL was dissolved in a few drops of glacial acetic acid, then diluted
with deionized water, and the pH adjusted with a IM sodium hydroxide solution. Drug
doses are expressed in terms of the weight of their bases, except for chloral hydrate and
SCH, which are provided as the salt.

Results

Electrophysiolo2ic Characteristics of Extracellularly Recorded Neurons
in the VP/SI
One hundred twenty five histologically verified VP/SI neurons were investigated
in the present study (Fig. 2). Of these spontaneously active VP/SI neurons, 114 (913)
displayed biphasic and 11 (93) had triphasic action potential configurations. The mean
duration of the action potentials was 1.3 ± 0.04 ms, and the peak to peak amplitude was
370 ± 22 µV. One hundred three recordings (823) had initially negative action
potential waveforms, and the remaining 22 (183) had initially positive waveforms.
VP/SI neurons demonstrated regular, irregular, or bursting firing patterns (Fig. 3) with
an average firing frequency of 11.5 ± 0.74 spikes/s. The most frequently encountered
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Fig. 2. STEREOTAXIC MAPS ILLUSTRATING THE HISTOLOGICAL
LOCATIONS OF NEURONS WITHIN THE VP/SI FROM WHICH
EXTRACELLULAR POTENTIALS WERE RECORDED (maps obtained from Paxinos
and Watson, 1986). The side from which each neuron was recorded is indicated by L,
left or R, right; and many recording sites overlapped. Anterior-posterior locations of
brain sections are indicated in millimeters from Bregma by the number of each section.
AC, anterior commissure; SI, substantia innominata; STR, striatum; VP, ventral
pallidum.
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Fig. 3. OSCILLOSCOPE TRACES ILLUSTRATING THE CHARACTERISTICS
OF ACTION POTENTIALS AND FIRING PATTERNS RECORDED FROM
NEURONS LOCATED IN THE VP/SI. The most frequent recording encountered had
~n initially negative, biphasic action potential and a slow, irregular firing rate as
llh.~strated in (A). Neurons with large, initially positive action potentials and bursting
activity as illustrated in (C) were encountered least frequently. Up is positive.
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recording displayed an irregular firing pattern often demonstrating slow cyclic increases
and decreases in rate (illustrated by histograms in Fig. 6A-B).

Effect of Cumulative Doses of the Selective Di DA Receptor Aeonist.
Quinoirole. on the Activity of VP/SI Neurons
QUIN was administered to determine the effects of DA Di receptor activation on
the firing rate of VP/SI neurons. Firing rates following injection of vehicle solutions in
volumes similar to those for agonist treatments did not meet the criteria for a druginduced rate change (N = 13 neurons). In contrast, injections of 0.1 - 25.6 mg/kg of
QUIN decreased firing rate in 16 of 26 neurons tested (Table 1). The activity of 7
neurons ceased with the 0.2 mg/kg dose of QUIN, and thus, were not included in the
dose-response curve presented in Fig. 4B. The magnitude of the rate suppression in the
other 9 sensitive neurons at 0.1 mg/kg of QUIN was significant, and administration of
higher doses of the agonist did not decrease firing rate further. Responses of the 10
remaining neurons tested with these doses of QUIN are summarized in Table 1.
Many VP/SI neurons responded to 0.1 mg/kg of QUIN, and additional doses
did not induce further rate changes (Fig. 4B), suggesting that maximal responses were
attained with this dose. Thus, 12 VP/SI neurons were tested with lower doses of
quinpirole (0.002 - 0.2 mg/kg, i.v.) to determine if VP/SI neurons were sensitive to
these doses, and if these changes in firing rate were dose-dependent. As illustrated in
Fig. 4A-B, firing rate of 6 neurons decreased in a dose-dependent manner with a
maximal decrease of 40% below control rates and an ED50 of 7.6 µg/kg. Responses of
the remaining 6 neurons were equally distributed between a slight increase in firing rate
(Fig. 4C) or an insensitivity to agonist administration (Table 1).
The decrease in activity of only half of the neurons tested with a total dose of
25.6 mg/kg of QUIN was abated after administration of the selective D2 antagonist,
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SUL (12.5 or 25.6 mg/kg, i.v. and 1 neuron was tested and antagonized with 50
mg/kg). SUL administration antagonized only 2 of the 6 cells that responded with
QUIN-mediated increases, and 2 of 3 with biphasic rate changes. Furthermore, the
average firing rate recorded after administration of 25.6 mg/kg of QUJN or after a
subsequent injection of SUL was not different (Table 2). In contrast, SUL (12.5
mg/kg, i.v.) reversed the decrease in firing rate of all 6 neurons tested with a 0.2 mg/kg
total dose of QUIN (Fig. 4A), as well as 1 of 3 cells excited by this dose of QUIN. The
firing rate of responding neurons was different between QUIN plus SUL and the
agonist alone at the lower agonist concentration (Table 2).
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Fi~. 4.
RESPONSES OF VP/SI NEURONS TO CUMULATIVE DOSE
ADMINISTRATION OF QUINPIROLE (QUIN). (A) A histogram illustrating the
effects of dopamine D2 receptor stimulation by low doses of QUIN. The decrease in
firing rate mediated by QUIN was reversed by sulpiride (SUL). (B and C) Cumulative
dose-response curves summarizing the effects of intravenous administration of QUIN
on the spontaneous activity of VP/SI neurons. In (B), six of 12 cells tested with low
doses of QUIN responded with dose-dependent decreases in activity (open triangles; df
= 5, r = -0.92, p < 0.01). The decreases in firing rate of 9 neurons following
administration of 0.1 - 25.6 mg/kg of QUIN did not correlate with dose (df = 7, r =
0.08, p > 0.1 ). (C) Increases in firing rate occurred in 3 neurons after administration of
Jow doses; and 6 cells after high doses of QUIN that was dose related (df =7, r = 0.79,
p < 0.05). Three cells that demonstrated biphasic responses are not represented. N is
the number of VP/SI neurons included in each curve.
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TABLE 1
SUMMARY OF RESPONSES OF VP/SI NEURONS TO SYSTEMIC
ADMINISTRATION OF SELECTIVE OOPAMINE RECEPTOR AGONISTS
In the experiments involving a dose range, dopamine ~gonists w~e. administered at
2 min intervals such that each dose added to the previously adm1mstered dose. In
the remaining experiments, quinpirole or SKF38393 was administered as a single
injection of the dose indicated.
Response'l

Agonist
(doses)

Increase(%) Decrease(%) Biphasic (%) No Effect (3)
Quinpirole
(0.1 - 25.6 mg/kg)h,c

6/26 (23)

(0.002 - 0.2 mg/kg)

3/12 (25)

6/12

(50)

(0.1 mg/kg)

3/13 (23)

8/13

SKF38393
(0.1 - 25.6 mg/kg)h,c

17/25 (68)

(0.002 - 1.6 mg/kg)
(3.2 mg/kg)

3/26 (11.5)

1/26 (4)

0112

(0)

3/12 (25)

(62)

0/13

(0)

2/13 (15)

4/25

(16)

0/25

(0)

4125 (16)

6/13 (46)

4/13

(31)

1/13

(8)

2/13 (15)

19/23 (83)

1/23

(4)

0123

(0)

3/23 (13)

16/26 (61.5)

a The ratio of responding cells divided by total number tested. Chi-square
analysis of the distribution of responses following the administration of SKF38393
versus that following quinpirole administration indicated that the number of cells
that increased, decreased or were unaffected is dependent on the agonist
administered (df = 3; x2 = 28.91; p < 0.01).

h The distribution of responses following administration of high and low doses of
quinpirole, or high and low doses of SKF38393 was not significant (df = 3; x2 =
5.08, 3.49; p > 0.1, respectively).
c The distribution of responses following administration of cumulative versus
single doses of quinpirole and SKF38393 also was not significant (df = 6; x2 =
6.42, 9.35; p > 0.1, respectively).
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TABLE 2
SUMMARY OF ANfAGONISM OF DA AGONIST-INDUCED EXOTATION OF
VP/SI NEURONAL ACTIVITY
Neurons that were excited by quinpirole (total dose 0.2 or 25.6 mg/kg) were tested
with sulpiride (SUL; 12.5 or 12.5-50 mg/kg, respectively). Neurons that were
excited by SKF38393 (total dose 1.6 or 25.6 mg/kg) were tested with SCH (0.1-0.4
mg/kg). In addition, SCH (0.1 mg/kg) and SUL (12.5 mg/kg) were injected in 10
min intervals to 11 neurons that responded to a single dose of SKF38393 (3.2
mg/kg).
Agonist
(doses)
Quinpirole
25.6mg/kg
0.2 mg/kg
0.1 mg/kg

SKF38393
25.6mg/kg
1.6 mg/kg
3.2 mg/kg

Antagonist
Treatment No. 1
Treatment No. 2

Response
3 control
Increase

SUL

SUL+ SCH

296±123.9
137 ± 30.3
159 ± 21.7

292 ± 89.1
144 ± 17.6
120 ± 16.98

..........
..........
..........

Increase

SCH

SCH+ SUL

162 ± 15.4
180 ± 29.1
179 ± 9.4

115 ± 16.lb
123 ± 19.2C
133 ± 15.3d

..........
..........
105 ± 12.9d

The mean percent response to agonist administration was different than the mean
response after subsequent injection of antagonists: a df = 5, F = 24.33; b df = 25, F =
4.76; c df = 11; F = 7.81; p < 0.05.
d The mean percent response to SKF was different from the responses following SCH
or subsequent injection of SUL (SCH + SUL); repeated measures ANOV A: df = 29,
F = 17.68, and Tukey's HSD for SCH or SCH + SUL from SKF: df = 18, p <
0.01). However, SCH+ SUL was not different from SCH (df = 18, p > 0.05).
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T ABI...E 2 - Continued

sUMMARY OF ANTAGONISM OF DA AGONIST-INDUCED SUPPRESSION
OF VP/SI NEURONAL ACTIVITY
Neurons that were inhibited by quinpirole (total dose 0.2 or 25.6 mg/kg) were tested
with sulpiride (SUL; 12.5 or 12.5-50 mg/kg, respectively). In addition, SUL (12.5
mg/kg) was injected 10 min after quinpirole was administered as a single dose of 0.1
mg/kg, and SCH23390 (SCH; 0.1 mg/kg) was administered 10 min after SUL in 2
neurons. Neurons that were inhibited by SKF38393 (total dose 1.6 or 25.6 mg/kg)
were tested with SCH (0.1-0.4 mg/kg). In addition, SCH (0.1 mg/kg) and SUL
(12.5 mg/kg) were injected in 10 min intervals to 11 neurons that were inhibited by a
single dose of SKF38393 (3.2 mg/kg).

Agonist
(doses)
Quinpirole
25.6mg/kg
0.2 mg/kg
0.1 mg/kg

SKF38393
25.6mg/kg
1.6 mg/kg
3.2 mg/kg

Response
3 control

Antagonist
Treatment No. 1
Treatment No. 2

Decrease

SUL

SUL+ SCH

42± 8.8
58± 9.9
50± 6.1

65 ± 15.0
99± 5.ia
74±11.4h

..........
..........
50 ± 13.6

Decrease

SCH

SCH+ SUL

33 ± 26.3
52 ± 15.4
6d

57± 6.0
104 ± 14.JC
62

..........
..........
76

The mean percent response to agonist administration was different than the mean
response after subsequent injection of antagonists: a df = 11, F = 10.49; b df = 15, F
= 7.76; p < 0.05; c df = 7, F = 26.54, p < 0.01.
d Only one neuron was suppressed by administration of SKF38393.
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Effect of Cumulative Doses of the Selective D1 DA Receptor Aeonist,

--Sf<F38393,

on Activity of VP/SI Neurons

SKF was administered to investigate the responsiveness of VP/SI neurons to D1
receptor stimulation. Cumulative dose administration of 0.1 - 2S.6 mg/kg SKF altered
the firing rate of 21 of 2S neurons tested (Fig. SB-C). Seventeen neurons displayed
dose-dependent increases in firing rate to agonist administration (Fig. SA-B), and 4
neurons were suppressed (Fig. SC).
Unexpectedly, many VP/SI neurons responded to low doses of SKF (e.g. 0.1
mg/kg) that were below those necessary to induce responses in other dopaminoceptive
brain regions (e.g., 20 mg/kg for the GP; Carlson et al., 1987a), suggesting that VP/SI
neurons may be more sensitive to this agonist. Thus, lower doses (0.002 - 1.6 mg/kg)
of the agonist were tested on an additional 13 VP/SI neurons, and rate increases were
observed in 6 of these (Fig. SB). The responses illustrated in both the high and low
dose SKF curves were dose-related.

The EDso of the SKF-induced increases,

determined by combining the responses for 0.2 - 6.4 mg/kg doses in both cumulative
dose studies, was 0.9 mg/kg, and the Emax was 1623 of control firing rate. The
responses of the remaining 7 neurons tested with low doses of SKF are illustrated in
Fig. SC and summarized in Table 1.
Administration of the selective D1 antagonist, SCH (0.1 - 0.4 mg/kg, i.v.)
antagonized the SKF-induced excitation of 10 of the lS neurons tested with a total dose
of 2S.6 mg/kg, but only 1 of 4 suppressions (Fig. SA). SCH injection antagonized 4 of
the 6 neurons with increased rates, all 4 of the decreases, and the last phase of the
biphasic response, for neurons tested with a total dose of 1.6 mg/kg of SKF. The
responses to antagonist treatment differed from the SKF-induced excitations for both
dose ranges, and for the neurons with decreases in rate after injection of a total dose of
1.6 mg/kg of SKF (Table 2).
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Fig. 5.
VP/SI NEURONAL RESPONSES TO ADMINISTRATION OF
CUMULATIVE DOSES OF THE D1 RECEPTOR AGONIST, SKF38393 (SKF). (A)
A histogram depicting a rate increase induced by SKF. The D1 specific antagonist,
SCH23390 (SCH) attenuated the response. (B and C) Cumulative dose-response
curves illustrating the effects of SKF on single unit neuronal activity of the VP/SI. (B)
Six neurons displayed dose-dependent increases in firing rate following injection of low
doses of SKF (df = 8, r = 0.69, p < 0.05). An additional 17 of 25 neurons exhibited
dose-dependent increases in firing rate after administration of higher doses of SKF (df =
4, r = 0.87, p < 0.05). Rate increases with 0.1 - 1.6 mg/kg of SKF38393 were not
different in the two experiments (df = 1, 20, F = 2.28, p > 0.1 ). (C) Decreases in firing
rate following administration of low doses of SKF occurred in 4 neurons, and also in 4
neurons that received high doses of the agonist. In addition, one neuron (not illustrated)
demonstrated a SKF-mediated biphasic response, the last phase of which was blocked
by SCH. N is the number of cells.
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Effect of Sin2le Injections of Dopaminer2ic Aeonists on the Firin2 Rate

!!f

VJ>/SI Neurons
Electrophysiologic studies have demonstrated that DA agonist pretreatment can

attenuate the effect of higher doses of the same agonist in GP neurons (Bergstrom et al.,
1984). To determine whether different schedules of administration influence the
magnitude or direction of the responses of VP/SI neurons, effects of single injection
treatments of QUIN and SKF were tested. Doses of the agonists selected were those
that resulted in near Emax responses as determined from the above studies (i.e., 0.1
mg/kg for QUIN and 3.2 mg/kg for SKF). The firing rate of 8 of 13 (623) neurons
tested with QUIN decreased, and 19 of 23 (833) neurons tested with SKF increased
(Fig. 6B-C). Eight of9 neurons that demonstrated a Di-mediated excitation were tested
with vehicle solutions. Vehicle treatments did not affect the ongoing increase in firing
rates, and SKF-induced rate increases lasted for at least 20 min (Fig. 6A). The average
suppression induced by a single injection of QUIN was 50 ± 6.1 %, which was not
different from the response following a cumulative dose of 0.1 mg/kg QUIN (mean: 62

± 103; df = 12, t

= -1.02, p

> 0.1). The average increase in firing rate induced by

administration of SKF38393 was 228 ± 373, which was not different from the
response after a 3.2 mg/kg cumulative dose of the same agonist (mean: 174 ± 19%; df =
34, t = 1.25, p > 0.1). Responses of the other neurons tested with QUIN or SKF are
provided in Table 1.
SUL (12.5 mg/kg) injected 10 min after administration of QUIN attenuated the
agonist-induced decreases in 5 of 8 (633) neurons (Fig. 6C), and 1 of 2 remaining
neurons tested was attenuated with a subsequent injection of 0.1 mg/kg of SCH. Firing
rates following initial administration of QUIN were different from those observed with a
subsequent injection of SUL (Table 2).
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Fig. 6. VP/SI RESPONSES TO INJECTION OF SINGLE DOSES OF SKF38393
(SKF) AND QUINPIROLE (QUIN). (A and B) Rate histograms illustrating the
increase in firing rate of VP/SI neurons after administration of single 3.2 mg/kg dose of
SKF. (A) Administration of a 0.33 tartaric acid solution (TT A), the vehicle for
SCH23390 (SCH) injected in volumes equal to those used for the antagonist, did not
alter the SKF-induced rate increase. This recording depicted one of the more marked
rate increases in response to SKF, but the duration of agonist induced excitation (more
than 1 h) was similar to responses of other VP/SI neurons. (B) A dose of 0.1 mg/kg of
SCH attenuated the SKF-induced increase, and a subsequent injection of sulpiride
(SUL) reduced neuronal firing to pretreatment rates. (C) A histogram illustrating the
rate decrease frequently observed following administration of 0.1 mg/kg of QUIN.
Subsequent injection of SUL antagonized this D2-mediated response.
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Ten neurons demonstrating SKF-induced increases also were tested with SCH,
and the response of 7 of these was attenuated by SCH. A subsequent injection of SUL
reversed rates to pretreatment levels or below in these 7, as well as an additional 2 of the
1o neurons. The firing rate change induced by SKF was different than that after
administration of SCH, as well as the subsequent SUL injection (Table 2).

,Comoarison of D1- or D2-mediated Responses
The distribution of responses to SKF (i.e. the number of neurons with increased
or decreased activity, and the insensitive neurons) versus that following QUIN was
conditional to the agonist administered (Table 1). QUIN- or SKF-induced responses
were antagonized more often when lower doses rather than higher ones were
administered (Table 2). SKF-induced increases in firing rate were attenuated by SCH
administration at each dose ranges tested, suggesting that the response to SKF was
selectively mediated by D1 receptor activation even at a total dose of 25 mg/kg of the
agonist (Table 2). In contrast to the selectivity of SKF for the D1 receptor at high
doses, QUIN-induced decreases were attenuated by SUL at the 0.2 mg/kg, but not at
the 25.6 mg/kg total dose of the agonist (Table 2), suggesting that these high doses of
QUIN may induce nonselective alteraction of VP/SI activity.

Discussion

The present experiments demonstrated that VP/SI neurons were sensitive to
intravenous administration of either D1 or Di agonists, and that the specific activation of
the distinct receptor subtypes produced opposite effects on activity of these neurons.

Di

DA receptor stimulation altered the firing rate in 45 of 51 (88%) neurons tested with
QUIN, and rate suppressions were observed in 30 of 51 (593) neurons. Responses to
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0.002 _ 0.2 mg/kg of QUIN were usually attenuated, and the rate decreases were
reversed completely by SUL administration verifying that the agonist-induced effects
involved Di receptor activation for this dose range. The effects of QUIN in the present
study occurred at doses that facilitate defense behaviors in cats (Sweidan et al., 1990),
indicating that the systemically administered doses used in the present study are
behaviorally relevant.
D1 DA receptor stimulation by SKF altered neuronal activity in 52 of 61 (853)
VP/SI neurons tested. In contrast to QUIN-induced responses, SKF increased firing
rate in 42 of 61 (693) neurons. The specific D1 receptor antagonist, SCH was more
effective in attenuating the responses to lower doses of SKF, but agonist-induced
increases were attenuated in approximately 703 of all neurons tested. The agonistinduced effects in the present study occurred at doses that also induce grooming in rats
(Meller et al., 1988; Vasse et al., 1988) indicating that these systemically doses are
sufficient to influence neuronal activity and behavior. Thus, behaviorally relevant doses
of QUIN and SKF administration altered VP/SI neuronal activity in opposite directions
via stimulation of specific receptor subtypes.
Although the VP/SI is a ventral extension of the GP with similarities in cell
morphology and neurotransmitter content, the present study revealed that the effects of
D1 or D1 DA agonists on VP/SI neuronal activity contrasts with those previously
demonstrated in the GP. For example, 713 of VP/SI neurons tested responded by the
0.2 mg/kg dose of QUIN, whereas 0.3 mg/kg of QUIN affects only 543 of GP
neurons tested (Carlson et al., 1988). The predominant response direction observed for
the

Di agonist also differs for each area; activity of VP/SI neurons decreased, but GP

neurons respond with excitation (Carlson et al., 1987a, 1988). D1 receptor activation
initiated responses in 52of61 (853) VP/SI neurons tested with SKF doses that were
less than 6.4 mg/kg. GP neurons are insensitive to these doses, and at 20 mg/kg SKF,
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only 54% of the recorded neurons are affected (Carlson et al., 1988). Furthermore,
dopaminergic agonist pretreatment in the GP diminishes the effect of subsequent
administration of higher doses of the same agonist (Bergstrom et al., 1984); a
phenomenon that was not observed for the VP/SI in the present study. Thus, changes
in activity induced by systemically administered DA agonists discriminate between
VP/SI and GP neurons.
To determine the contribution of DA receptor subtypes in agonist-induced
responses of VP/SI neurons, both D1 and

Di

antagonists were administered after

agonist treatments if the first antagonist did not attenuate the agonist-induced response.
Decreases induced by single dose treatment of QUIN usually were attenuated with SUL,
and subsequent administration of SCH was tested on only two neurons. These results
suggest that the effects induced by quinpirole were mediated through

Di

receptor

activation without involving the D1 receptor. In contrast, SCH attenuated the effects of
SKF, although subsequent administration of SUL often reduced rates to or below
control levels. These results imply that SKF-mediated effects of VP/SI neurons may
involve the

Di receptor.

However, SUL administration alone has been observed to

suppress VP/SI activity (unpublished results). Thus, SUL-induced rate suppression
may not be due to antagonism of the response to SKF, but through a blockade of a
tonically active dopaminergic input. This would explain the observation that SUL was
able to induce rate decreases that surpassed pretreatment levels in the present study.
An additional interpretation involves the possibility that endogenous DA is
released by SKF, and the neurotransmitter acts at the D1 receptor to contribute to the
SKF-mediated response. Carlson et al. (1988) observed that the electrophysiologic
effects of high doses of SKF in the GP are attenuated by removal of endogenous DA.
However, pharmacologic inactivation of central dopaminergic systems did not eliminate
SKF-induced rate increases in the VP/SI (Maslowski et al., 1990), suggesting that the
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expression of SKF-induced responses may involve, but do not require, dopaminergic
systems. Further studies are necessary to determine if removal of endogenous DA
eliminates the ability of SUL to influence SKF-induced responses in the VP/SI.
The present experiments suggest that Di and

Dz receptors fulfill oppositional

roles in mediating VP/SI neuronal activity. In addition, the VP/SI generates cueelicited, event-related potentials in the cortex (Pirch et al., 1986; Rigdon and Pirch,
1986), and these slow potentials respond in opposite directions to D1 and

Dz agonists

(Pirch et al., 1988). These observations concur with the opposite effects of these
agonists in the modulation of adenylate cyclase (Stoof and Kebabian, 1981). In
contrast, many studies of other dopaminoceptive brain regions demonstrate that
responses to Di or Dz receptor activation are in the same direction (e.g., Carlson et al.,
1988). Thus, the VP/SI may be unique in its responses to separate administration of
DA agonists selective for receptor subtypes.
The location of DA receptor subtypes that mediate agonist-induced alterations in
firing rate of VP/SI neurons has not been determined. Receptors located within the
VP/SI as well as inputs from other dopaminoceptive brain regions may contribute to
responses observed after systemic administration of DA agonists. Previous studies
indicate that approximately 403 of the VP/SI neurons sampled are sensitive to
microiontophoretic application of DA, and rate suppression was observed more often
than excitation (Napier et al., 199lb). Thus, inhibitory effects of the DA agonists
demonstrated in the present study may reflect receptor activation within the VP/SI.
Although NA inputs to VP/SI are substantial (for review see, Heimer et al.,
1985), and the dopaminergic modulation of this input increases activity in the VP/SI,
microinjection of QUIN or SKF individually in the NA does not alter VP/SI activity (for
review see, Mogenson and Yang, 1991). In addition, inactivating the NA with procaine
microinjections does not eliminate responses of VP/SI neurons to systemic
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administration of QUIN or SKF (Napier, 1990). Thus, the responses of VP/SI neurons
in the present study may be independent of NA inputs.
Alteration of dopaminergic projections from the midbrain is another means that
VP/SI activity could be changed by systemic administration of DA agonists. However,
the contribution of this input may be modest since pharmacological suppression of
midbrain dopaminergic neuronal activity by systemic pretreatment with gammabutyrolactone, did not eliminate the effects induced by systemic administration of either
QUIN or SKF (Maslowski et al., 1990).
AMN neurons also project to the VP/SI (for review see Zaborszky et al., 1991).
In addition, the AMN receives dopaminergic inputs from the midbrain (for review see,
De Olmos et al., 1985). The activity of AMN neurons is altered by systemic
administration (Bashore et al., 1978) and local application (Nakano et al., 1987) of DA
agonists. Preliminary evidence suggests that inactivation of the AMN by local injection
of procaine, attenuated the responses to systemically administered SKF (Napier,
unpublished results). Thus, the effects of systemic administration of dopaminergic
agents may involve the summated activation of DA receptors within VP/SI, as well as
indirect influences from the AMN afferents to the VP/SI.
Dopaminergic modulation of neuronal activity may propagate changes in the
transmission of VP/SI efferents. The VP/SI is located between projection neurons of
extrapyramidal motor (for review see, Mogenson and Yang, 1991) and limbic systems
(Haber et al., 1985) which may permit the VP/SI the capacity to integrate motoric,
cognitive, and motivational processes. For example, neuronal activity is enhanced in
VP/SI when an animal performs task-related movements and during appropriate
responses to rewarded stimuli (for review see Richardson and Del.ong, 1991). Recent
findings indicate that the VP/SI is involved in alterations of specific behaviors in the rat,
including cocaine self-administration (Hubner and Koob, 1990). Changes in firing rate
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of VP/SI neurons in response to DA activation ofD1 or Di receptors may mediate these
behaviors, thus underscoring the importance of continued investigation of the
dopaminergic influence on VP/SI neurotransmission.
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CHAPTER IV
EFFECTS OF D1 AND D2 ANTAGONISTS ON APOMORPIIINEINDUCED
RESPONSES OF VENTRAL PALLIDAL NEURONS

Abstract

The ventral pallidum and adjacent substantia innominata (VP/SI) is innervated by
dopaminergic terminals and contains Di and

Di DA

receptors. Repeated systemic

injections of the DA agonist, apomorphine (APO), induce dose-dependent alterations in
VP/SI neuronal activity. The present studies evaluated the contribution of Di and D1
receptor subtypes to APO-induced alterations in extracellularly recorded VP/SI neuronal
activity. Both sulpiride (SUL; D1 antagonist) and SCH23390 (SCH; Di antagonist)
attenuated many of these responses; however, pretreatment with either antagonist did
not alter the number of responding neurons, or the maximal effect induced by APO.
Thus, activation of either receptor subtype by APO is sufficient to initiate the observed
responses, and both may be involve in dopaminergic modulation of VP/SI neurons.

Introduction

The ventral pallidum and substantia innominata (VP/SI) are basal forebrain
regions involved with the processing and transmission of motor, cognitive and
motivational functions. Dopaminergic modulation of these behaviors may occur since
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the activity of VP/SI neurons is affected by manipulation of dopaminergic systems. The
VP/SI is directly innervated by dopaminergic inputs (Voorn et al., 1986), and both D1
and D2 DA receptor subtypes are present in this area (Contreras et al., 1987). VP/SI
neurons demonstrate dose-dependent changes in firing rate after intravenous
administration of the D1/D2 DA agonist, APO (Napier et al., 199lb). In the dorsal
globus pallidus (GP), which is morphologically similar to the VP/SI, APO stimulates

Di and Di receptor subtypes, and both are necessary for maximal responding (Carlson

et al., 1987a). GP neuronal responses to APO also are attenuated when the agonist
dose is administered in multiple injections, a phenomenon the authors termed a "priming
effect" (Bergstrom et al., 1982).
The present electrophysiologic studies evaluated the contribution of DA receptor
subtypes to APO-induced effects in the VP/SI by determining (1) whether antagonists
selective for either the D1 or Di receptor influenced the effects of APO, and (2) whether
pretreatment with either antagonist precluded the agonist-induced effects. In addition, a
single dose of APO was tested to determine if the agonist-induced rate changes with this
protocol were higher than those obtained previously in this laboratory for the VP/SI
using the same dose administered in multiple injections (Napier et al., 1991b).

Methods

Extracellular activity of single VP/SI neurons was monitored in chloral hydrate
(400 mg/kg, i.p.) anesthetized, male Sprague-Dawley rats (270-330 g). Chloral hydrate
supplements were intravenously administered to maintain surgical levels of anesthesia.
Supplementation was discontinued prior to test treatments with DA agents. Only one
neuron per animal was tested. Action potentials (spikes) were recorded with a glass
pipette containing a 2 M sodium chloride solution saturated with fast green dye.
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Standard recording techniques were used as described elsewhere (Maslowski and
Napier, 1991 a). VP/SI neurons were recorded within the stereotaxic coordinates 0.5
mm p from Bregma, ± 2.5 mm L from the midline and 7.5-8.5 mm below the dura
(according to Paxinos and Watson , 1986). Stable baseline firing was obtained for 5
min, and treatments were then injected in 10 min intervals through a tail vein cannula.
The following vehicle solutions were tested in equal volumes to the respective
drug treatments: saline (0.12 ml) and 0.33 tartaric acid (0.19 ml), which were vehicles
for APO and SCH (D1 specific antagonist), respectively; and buffered acetic acid (0.19
ml; pH = 5), which was the vehicle for both SUL (D2 specific antagonist) and
haloperidol (D1/D2 nonselective antagonist). The dose of APO selected (0.5 mg/kg,
i.v.) is known to produce near maximal responding in VP/SI neurons (Napier et al.,
199lb), and the duration of APO-induced rate changes persists for longer than 20 min
(Napier et al., 1986). APO was administered as a single dose, followed at 10 min postinjection by SUL (12.5 mg/kg) or SCH (0.1 mg/kg). In 10 neurons tested with SCH,
haloperidol (0.5 mg/kg) was also administered to evaluate the possible role of D2
receptors in APO-induced effects. The antagonist doses selected are sufficient to
reverse APO-induced behavioral changes in rats (Kendler et al., 1982; Martres et al.,
1984; Molloy and Waddington, 1985).
In additional experiments, a 10 min pretreatment of SUL or SCH preceded APO
administration. These neurons were also tested with a saline vehicle before the
antagonist pretreatment. Neurons that remained sensitive to APO after competitive
antagonism of one receptor subtype, subsequently were tested with the specific
antagonist for the other subtype. Responses were considered significant if baseline
firing was altered by greater than 203. Antagonism was defined as an attenuation of
agonist-induced responses by at least 303. A more stringent criterion than that for
agonist-induced responses was select to assess antagonism since most of the antagonist
66

effects exceeded the usual 203 criterion. At the end of each experiment, the rat was
overdosed with chloral hydrate, and the recording site was determined by the
histological location of a fast green dye deposit from the electrode tip (Maslowski and
Napier, 1991a).
Neuronal activity after drug injections is presented as mean percent of
pretreatment activity ± S.E.M., determined by comparing the firing rate averaged over
the last minute of pre-drug period (considered as 1003) with that observed during the
last minute interval following each injection. Alterations in mean firing rate among
different drug treatments or time intervals were evaluated with repeated measures,
ANOVA and t - test. Differences in the distribution of effects were examined with Chisquare analysis. The criterion of significance for all statistical tests wasp < 0.05.

Results

Sixty-five neurons were recorded within the VP/SI (Fig. 7). These VP/SI
neurons displayed biphasic, and infrequently triphasic, action potentials with a mean
duration of 1.4 ± 0.04 ms, and peak to peak amplitude of 350 ± 20 µV. VP/SI neurons
demonstrated regular, irregular, or bursting firing patterns with an average firing
frequency of 10.5 ± 1.0 spikes/s. APO induced responses in 28 of 35 (803) neurons
tested (eg., Fig. 8), and 7 were insensitive (data not shown). The average rate
suppression (N=15, 64 ± 83 below baseline rate; baseline= 1003) and excitation
(N=l3, 105 ± 293 above baseline) induced by this single injection of APO were similar
to responses previously observed after a cumulative dose of 0.5 mg/kg administered in
multiple injections (95 ± 53 and 96 ± 123, respectively Napier et al., 1991). Neuronal
activity was not affected by vehicle solutions in all 7 neurons tested using the protocol
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for drug treatments, nor by saline injected prior to antagonist pretreatments in 20 of 23
neurons tested.
The magnitude of the difference between APO-induced rate suppression
compared to excitation was not statistically significant (df = 26, t

= 1.45, p > 0.1), and

the Di or D2 DA receptor-selective antagonists demonstrated a similar capability to
attenuate APO-induced effects regardless of the agonist-induced response direction.
Thus, the data were combined omitting direction of responses (Table 3). SUL
attenuated the effects of APO in 5of12 neurons tested, and SCH antagonized 11of16
neurons tested (eg., Fig. 8; Table 3). In 10 neurons, haloperidol was administered after
SCH, and did not potentiate the SCH-induced antagonism in 8 neurons, but attenuated
the APO-induced responses in 2 of 4 neurons that were not affected by SCH (data not
shown).
APO effects also were evaluated after pretreatment with either SUL or SCH to
determine whether functional removal of either receptor subtype would eliminate APOinduced effects. Four of 12 (333) neurons pretreated with SUL, and 1 of 11 (93)
pretreated with SCH were insensitive to APO. The APO-induced effects of these 5
VP/SI neurons appear to be mediated specifically through one receptor subtype.
However, APO mediated responses through either receptor subtype in the majority of
neurons tested. Thus, the proportion of APO sensitive compared to insensitive neurons
was unaltered by antagonist pretreatment (df = 2; x2 = 2.08; p > 0.1). The magnitude
of APO-induced effects was also unchanged (df = 2, 43; F = 0.96; p > 0.1 ).
Table 3 illustrates the effects of antagonist pre- and post-treatment on APOinduced responses in VP/SI neurons. The ratios indicate the number of neurons
responding to a treatment compared to the number tested. For both SUL and SCH posttreatment groups, this is the number of APO-sensitive neurons whose agonist-induced
response was attenuated by greater than 303 by the antagonists, compared to the
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number of APO-sensitive neurons tested with the antagonists. Following pretreatment
with SCH or SUL, the proportion of neurons that were sensitive to APO and
subsequently antagonized by SUL or SCH post-treatment (df = 1, x2 = 1.02; x2 = 1.07,
p > 0.1, respectively), was not different from neurons tested without antagonist
pretreatment.
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l.Omm

Fig. 7. STEREOTAXIC MAPS ILLUSTRATING THE HISTOLOGICAL
LOCATIONS OF EXTRACELLULAR RECORDING SITES WITHIN THE
VENTRAL PALLIDUM (maps obtained from Paxinos and Watson, 1986. Reproduced
with kind permission from: The Rat Brain in Stereotaxic Coordinates. 2nd edition;
copyright 1986, Academic Press, Orlando, Florida). Three recording sites were also
!ocated (in the section labeled - 0.80) media] to the ventral pa1lidum within the substantia
mnominata. The number on each map indicates the distance posterior to Bregma in
millimeters.
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TABLE 3
EFFECT OF ANTAGONIST PRE- AND POST-TREATMENT ON
APOMORPHINE-INDUCED RESPONSES BY VP/SI NEURONS
Antagonist Pretreatment3
Antagonist
Post-treatmentb
Sulpiride
SCH23390

None
n (%)

Sulpiride
n (%)

SCH23390
n(%)

5112 (42)

........

6/8 (75)

11/16 (69)

4/10 (40)

........

a Animals receiving an antagonist pretreatment were injected with sulpiride (12.5

mg/kg, i.v.) or SCH23390 (0.1 mg/kg, i.v.) 10 min before the administration of
apomorphine (0.5 mg/kg, i.v.).
b Animals receiving antagonist post-treatment 10 min after the administration of
apomorphine.

Discussion

The present study revealed that activation of either the D1 or Dz receptor subtype
by APO was sufficient to induce neuronal rate changes in the VP/SI. The magnitude
and distribution of responses was similar among neurons receiving APO alone and after
either receptor subtype was blocked by pretreatment with specific antagonists. This
suggests that the receptor subtype that was not blocked by the antagonist is adequate to
maintain the response to APO. In agreement, previous experiments demonstrated that
stimulation of Dz receptors by the specific D2 agonist, quinpirole, or D1 receptor
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activation by the specific D1 agonist, SKF38393, is sufficient to alter VP/SI neuronal
activity (Maslowski and Napier, 199la).
The present study determined that the response magnitude of VP/SI neurons
after single dose of the APO was similar to that observed when the dose is achieved
through multiple injections (Napier et al., 1991 b). This contrasts with results reported
for the GP, where prior APO injection at a dose that does not induce a response,
attenuates the response to an effective dose of the agonist (termed a priming effect by
the authors; Bergstrom et al., 1982).

APO-induced responses of substantia nigra pars

reticulata neurons do not display a priming effect (Waszczak et al., 1984), and
additional studies in the VP/SI revealed that responses to quinpirole or to SKF38393
also do not exhibit priming (Maslowski and Napier, 1991a). Thus, absence of the
priming effect of APO may differentiate the VP/SI from the GP, but is not unique for
the VP/SI.
These studies illustrate that regional variations exist with regard to dopaminergic
influences, and underscore the necessity of obtaining pharmacological profiles for the
individual dopaminoceptive brain regions. The results demonstrate that stimulation of
one DA receptor subtype can alter neuronal activity within the VP/SI, which concurs
with previous experiments using agonists selective DA receptor subtypes (Maslowski
and Napier, 199la). Further studies are needed to determine if the responses involve
endogenous DA, and if these effects are mediated within the VP/SI or through other
dopaminoceptive regions that impinge upon the VP/SI.
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Conclusion

The present study indicates that activation of either the D1 or Di DA receptor
subtype is sufficient to initiate changes in VP/SI neuronal firing, and further supports
the independence of function for the subtypes.
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CHAPTER V
DOPAMINE WITHIN THE VENTRAL PALLIDUM MODULATES
NEURONAL ACTIVITY THROUGH Di AND Di RECEPTORS, AND
ATTENUATES VENTRAL PALLIDAL RESPONSES TO

AMYGI>AI~A

STIMULATION

Abstract

The ventral pallidum and adjacent substantia innominata (VP/SI) receive
dopaminergic afferents, demonstrate binding for D1 and Di dopamine (DA) receptors,
and intra-VP/SI DA application alters the firing rate of these neurons. The present
studies evaluated the effects of stimulating the ventral tegmental area (VTA) or the
substantia nigra pars compacta (SNc), which presumably releases endogenous DA
within the VP/SI, and of microiontophoretic application of DA within the VP/SI on the
spontaneous and amygdala-evoked activity of VP/SI neurons. The contribution of
VP/SI Di and D1 DA receptor subtypes to DA-mediated effects also was examined.
VP/SI neurons often responded to VTA/SNc stimulation with short latency(~ 12 ms)
inhibition, indicative of monosynaptically-mediated events. Intra-VP/SI application of
SCH23390 (a Di antagonist) or sulpiride (a Di antagonist) attenuated this response.
VTA/SNc-evoked VP/SI responses were mimicked by DA applied in the VP/SI. IntraVP/SI application of the Di agonist SKF38393 or the

Di agonist quinpirole modified

VP/SI activity, confirming that either receptor subtype can modulate VP/SI neuronal
activity. Thus, endogenously-released DA or exogenously-applied dopaminergic
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agonists alter(s) VP/SI neuronal activity via Di or Dz receptors. Stimulation of
amygdaloid nuclei (AMN) evoked short and long(> 12 ms) latency VP/SI responses,
and the effects of AMN and VTAfSNc stimulation converged extensively within the
VP/SI. Attenuation of AMN-evoked VP/SI responses was observed by: 1) prior
stimulation of the VTAfSNc, and 2) intra-VP/SI DA application. The results suggest
that activation of VTA/SNc releases DA within the VP/SI where it can act as a
physiological antagonist of AMN-evoked VP/SI responses.

Thus, DA displays

neuromodulatory effects on the activity of the ventral striatopallidal system at the level of
the VP/SI.

Introduction

The ventral pallidum (VP/SI), defined as the ventral subcommissural extension
of the globus pallidus, and the adjacent substantia innominata (Heimer and Wilson,
1975), receives ventral striatal and nucleus accumbens (NA) projections that transmit
limbic information from cortical and basolateral amygdaloid inputs (for review see,
Heimer and Alheid, 1991). The VP/SI can integrate and transmit this limbic information
to medial dorsal thalamic (Young et al., 1984) and brainstem regions (Swanson et al.,
1984) that govern motoric behaviors (Bruclzynski and Mogenson, 1985; Swerdlow and
Koob, 1987). Thus, the VP/SI, as a component of the ventral striatopallidal system,
"must participate in the execution and modulation of motor responses resulting from
various sensory and cognitive activities in the cerebral cortex" (Heimer and Alheid,
1991).
Midbrain dopaminergic neurons can influence the ventral striatopallidal system
via a dopamine-induced suppression of NA neuronal firing (Yim and Mogenson, 1982)
that may alter the activity of NA efferents to the VP/SI and result in VP/SI rate increases
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(Yang and Mogenson, 1989). Considerable evidence demonstrates that DA within the
NA can mediate locomotor activity via the VP/SI (Austin and Kalivas, 1991; Jones and
Mogenson, 1980; Mogenson and Nielson, 1983; Swerdlow et al., 1984). However,
recent studies indicate that dopamine (DA) within the VP/SI is sufficient to influence
VP/SI neuronal activity (Napier and Potter, 1989; Napier et al., 199lb) and locomotion
(Napier and Chrobak, 1992).
The VP/SI is innervated by midbrain dopaminergic neurons (for review see,
Napier et al., 1991 a; Zaborszky et al., 1991) that originate from both the ventral
tegmental area (VTA; Grove, 1988; Haring and Wang, 1986; Jones and Cuello, 1989;
Russchen et al., 1985; Semba et al., 1988; Zaborszky, 1989) and the substantia nigra
pars compacta (SNc; Fallon and Moore, 1978; Haring and Wang, 1986; Jones and
Cuello, 1989; Martinez-Murillo et al., 1988; Russchen et al., 1985; Semba et al., 1988;
Zaborszky, 1989), regions often associated with mesolimbic and extrapyramidal
motoric functions, respectively. Biochemical studies demonstrate the presence of DA
and its metabolites within the VP/SI (Geula and Slevin, 1989; Napier and Potter, 1989).
VP/SI neuronal activity frequently exhibits short latency inhibitory responses,
suggestive of monosynaptic effects, to the electrical stimulation of the SNc (Napier et

al., 199la), and often is inhibited by microiontophoretic applications of DA within the
VP/SI (Napier and Potter, 1989; Napier et al., 199lb).
Recent studies using molecular biological techniques reveal the existence of
several DA receptor subtypes within the brain (for review see, Civelli et al., 1991). The
effects of activating the Di and/or the

Di receptor

subtypes within the VP/SI were

examined in the present study. The D1 receptor subtype within the VP/SI was defined
pharmacologically by the ability of the selective D1 agonist, SKF38393 (SKF) to alter
VP/SI neuronal activity, and the attenuation of the agonist-induced effects by the
selective Di antagonist, SCH23390. Likewise, the D2 receptor subtype within the
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VP/SI was characterized by the actions of the selective Di agonist, quinpirole (QUIN),
and the attenuation of agonist-mediated effects by the selective Di antagonist, sulpiride
(SUL). Biochemical studies, using radioligands that selectively bind the Di or D1
receptor subtype confirm the presence of both receptor subtypes within the VP/SI
(Contreras et al., 1987; Beckstead et al., 1988; Napier et al., 1991a). Similarly, DAinduced alterations of VP/SI neuronal activity involve both receptor subtypes, since
systemic administration of SCH or haloperidol (a D1 antagonist) attenuates the
responses to systemic treatments of apomorphine (Maslowski and Napier, 1991 b) and
microiontophoretic applications of DA (Napier et al., 1991b). Previous studies indicate
that systemic activation of Di or D1 receptor is sufficient to alter the spontaneously
activity of VP/SI neurons (Maslowski and Napier, 1991a). However, it has not been
determined whether specific activation of Di or D1 receptor subtypes »ithin the VP/SI
can alter VP/SI neuronal activity. The involvement of these receptor subtypes in the
responses of VP/SI neurons to endogenously-released DA via electrical stimulation of
midbrain dopaminergic neurons is also unknown.
In addition to NA and midbrain dopaminergic inputs, amygdaloid nuclei (AMN)
provide limbic influences on the ventral striatopallidal system and subsequently affect
the activity of VP/SI efferents to brain regions involved with motoric behaviors. The
AMN, which is innervated by midbrain dopaminergic afferents (Fallon et al., 1978;
Fallon, 1981) and is influenced by administration of dopaminergic agents (Anderson
and Rebec, 1988; Bashore et al., 1978; Nakano et al., 1987), impinges directly onto
VP/SI neurons (Krettek and Price, 1978; Zaborszky et al., 1984; Price, 1986), as well
as providing afferents to the NA (Krettek and Price, 1978; Price, 1986). Evidence
from combined anatomical and histochemical studies indicate that AMN projections
contain the excitatory neurotransmitter, glutamate (or aspartate) (Fuller et al., 1987).
Electrical stimulation of the AMN usually excites NA neurons (Yim and Mogenson,
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1982), which presumably activates NA inhibitory efferents to the VP/SI to produce the
observed late onset (polysynaptic) inhibition of VP/SI activity (Yim and Mogenson,

1983). However, AMN stimulation also evokes short onset inhibitory and excitatory
effects on VP/SI neuronal activity that are independent of the NA (Yim and Mogenson,

1983), and may involve to some extent the direct innervation of the VP/SI by the AMN.
VTA stimulation (presumably releasing endogenous DA), attenuates the
monosynaptically-mediated, excitatory NA responses (Yim and Mogenson, 1982), as
well as the polysynaptically-mediated, inhibitory VP/SI evoked by AMN stimulation
(Yim and Mogenson, 1983). The modulatory effects of VTA stimulation are mimicked
by exogenously-applied DA within the NA. However, only a portion of the VTAinduced modulation of the AMN-evoked VP/SI responses is eliminated through
procaine-induced inactivation of the NA (Yim and Mogenson, 1983), suggesting other
pathways for DA modulation AMN-evoked VP/SI responses. Since both midbrain
dopaminergic and AMN afferents converge within the VP/SI, DA influences on AMN
inputs may occur within the VP/SI, providing additional processing of the information
transmitted to brainstem locomotor regions.
The present electrophysiological study was designed to address the following
questions: 1) Are the effects of intra-VP/SI DA application mediated through Di or D1
receptor subtypes within the VP/SI? 2) Are selective Di or D2 DA receptor agonists
within the VP/SI sufficient to induce rate changes in VP/SI neurons? 3) Does
stimulation of the VTA evoke similar responses in VP/SI neurons as SNc stimulation?
4) If the VTA/SNc influence VP/SI neuronal activity, are the evoked responses mediated
through Di and/or D1 receptor subtypes within the VP/SI? 5) Does VTA/SNc
stimulation modulate AMN-evoked activity of VP/SI neurons? 6) Does exogenouslyapplied DA within the VP/SI mimic the effects of VTA/SNc stimulation on VP/SI
neuronal activity?
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Materials and Methods

s_urgical Preparation of Animals
Male Sprague-Dawley rats weighing 250-350 g were anesthetized with chloral
hydrate (400 mg/kg, administered intraperitoneaJly; Sigma Chem. Co, St. Louis, MO).
A lateral tail vein was cannulated for intravenous injection of anesthetic supplements to
maintain surgical levels of anesthesia. The animals were then placed into a stereotaxic
apparatus (David Kopf Instruments, Tujunga, CA) with the nose piece set at 3.3 mm
below the horizontal, and the skull exposed. Coordinates used for recording the VP/SI
were 0.5 mm posterior to Bregma (P), 2.5 mm lateral to the midline (L) and 7.5-8.5
mm below dura (V). Those for the VTAfSNc were 5.7 mm P, 1.0 mm L for VTA and
1.6-2.0 mm L for SNc, 7.8-8.0 mm and 7.6-7.8 mm V for VTA and SNc, respectively.
Coordinates for the AMN were 2.8 mm P, 4.8 mm Land 7.2-7.5 mm V. Rectal
temperature of the animals was monitored throughout the experiments, and maintained
at 35-37°C with a thermostatically controlled heating pad (Fintronics Inc., Orange, CT).

Electrical Stimulation
Stainless steel concentric bipolar electrodes (NEX-100, 0.5 mm shaft diameter and
0.5 mm tip separation; David Kopf Instruments) were used for delivery of electrical
stimulation, generated by Grass S88 stimulators, each coupled to a Grass stimulation
isolation unit (SIU 5) and a Grass constant current unit (CCU 1; Grass Instrument Co.,
Quincy, MA). For experiments involving single pulse stimulation to the AMN or

VTA/SNc, monophasic pulses of 0.1 ms duration were applied at a frequency of 1 Hz
and with a current range of 0.05-1.5 mA (see Fig. 9). For experiments in which the
interaction of VTAfSNc with AMN on the activity of VP/SI neurons was examined, the
stimulation was sequenced as follows: 1) the VTAfSNc was stimulated with a train
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consisting of 10 pulses, each 0.1 ms in duration and the pulses within the train occurred
at a frequency of 10 Hz. 2) Following a delay of 100 ms, a single pulse of 0.1 ms
duration was delivered to the AMN. 3) The effect of this stimulation on VP/SI neuronal
activity was recorded for approximately 900 ms. 4) This entire VTA/SNc train - AMN
single pulse sequence was repeated at a rate of once every 2 s for 128 stimulation
epochs.
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Fig. 9. SCHEMATIC DRAWING ILLUSTRATING IBE ORIENTATION OF THE
MICROIONTOPHORETIC RECORDING ELECTRODE IN IBE VP/SI AND THE
STIMULATING ELECTRODES IN THE AMYGDALA AND VENTRAL
TEGMENTAL AREA (VTA) OR THE SUBSTANTIA NIGRA, PARS COMPACTA
(SNC). A single glass pipette used for recording action potentials within the VP/SI was
attached to five-barrel glass pipette that was used for microiontophoresis of
dopaminergic agonists and antagonists. Bipolar electrodes were used for: 1) single
pulse, orthodromic stimulation of the amygdaloid nuclei, often within the basolateral
nucleus of the amygdala (blA), and 2) either single pulses or a train of pulses to
orthodromically stimulate the VTA or SNc. See text for detailed description of
methods. nA - nanoAmps of current used to eject drugs from the microiontophoretic
electrode; µA - microAmps of current used for orthodromic stimulation of blA or
VTA/SNc.
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~tracellular

Sinele-Neuron Recordin2s and Microiontophoresis

Standard extracellular recording of single neurons and microiontophoresis
techniques were employed as described previously (Fig. 9; Napier et al., 199lb). Preassembled five-barrel glass pipettes (A-M Systems, Inc., Everett, WA) were pulled with
a vertical electrode puller (Narishige PE-2, Tokyo, Japan) and the tips broken back to 812 µm. A single barrel pipette, with a tip diameter of approximately 2 µm, was then
glued in parallel to the five barrel assembly such that the single barrel was positioned
below the five barrels by 8-15 µm. The single barrel, filled with 2 M NaCl saturated
with fast green dye (Fisher Scientific Co., St. Louis, MO), served as the recording
electrode. The in vitro impedance of the recording barrel was 3-6 MO, measured at 165
Hz with a micro-electrode tester (Winston Electronics, San Francisco, CA). The center
barrel of the five-barrel pipette also was filled with 2 M NaCl saturated with fast green
dye, and was using for automatic current balancing of the other barrels.
The remaining four barrels each contained one of the following drugs: DA
hydrochloride (0.2 M, pH 4; Sigma), quinpirole (QillN; LY 171555; trans-(-)-4aR4,4a,5 ,6, 7 ,8,8a,9-octahydro-5-propyl-1H (or 2H)-pyrazolo-(3,4-g) quinoline
monochloride; 0.01-0.02 M, pH 4; Lilly Research Lab., Indianapolis, IN), SCH23390
(SCH; (R)-( +)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-IH-3-benzazepin-7-ol
hemimaleate; 0.01 M, pH 4; Schering Corp., Bloomfield, NJ), SKF38393 (SKF;
2,3,4,5-tetrahydro-1-phenyl-lH-3-benzazepine-7 ,8-diol hydrochloride; 0.01 M, pH 4;
Research Biochemicals Inc., Natick, MA), and sulpiride (SUL; 5-(aminosulfonyl)-N((l-ethyl-2-pyrrolidinyl) methyl)-2-methoxybenzamide; 0.02 M, pH 4; Sigma). The
high concentration of agonists and antagonists used were selected to allow the passage
of ionized drug through high resistance (20-60MO) barrels of the microiontophoretic
pipette. Microiontophoresis of these agents (some of which have low solubility)
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necessitates the use of saturable concentrations to achieve satisfactory conductance
(Duggan, 1983; Salmoiraghi and Weight, 1967), and to minimize electrical noise on
drug ejection (Duggan, 1983). All drugs were dissolved in sterile deionized water, but
SCH and SUL were solubilized with HCl before being diluted to the final volume with
deionized water, and then ION NaOH was added until a pH of 4 attained.
In some experiments, the D1/Di dopamine receptor antagonist, flupentixol (4-[3[2-(trifluoromethyl)-9H-thioxanthen-9-ylidene] propyl)-1-piperazine ethanol
dihydrochloride; Research Biochemical Inc.) was injected through a lateral tail vein
cannula at a dose of 0.5 mg/kg. A concentration of 1 mg/ml of flupentixol was
dissolved in sterile water, and a pH of 4 was established by addition of ION NaOH.
For recording VP/SI neurons, the electrode assembly was lowered to 7.0 mm V,
and a six-channel current generator and programmer (Fintronics, Inc.) was used to
apply maximal ejection currents to each barrel for at least 30 min to concentrate the
drugs at the pipette tips. Drugs were ejected with cationic currents, and negative
retaining currents of 10 nA were applied to drug barrels between ejection periods.
Action potentials were sampled from the VP/SI (7.5-8.5 mm V) using a hydraulic
microdrive (Trent Wells, South Gate, CA), were filtered (200 Hz and 2 KHz) via a
high-impedance amplifier (Fintronics, Inc.), and monitored on an oscilloscope
(Tektronix Inc., Beaverton, OR) and audiomonitor (Grass Instruments Co.). To
quantify the neuronal activity, the digital output from the window discriminator
(Fintronics, Inc.) was transmitted to an IBM AT compatible computer, and Brainstorm
Systems Spikes to Stats software (Chapel Hill, NC) was used to display rate histograms
and to store and analyze data.
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Collection and Analysis
For experiment 1, it was determined if VP/SI neuronal responses to

microiontophoretically-applied DA were mediated through the Di and/or the

Di DA

receptor subtype within the VP/SI by assessing DA response attenuation produced by
locally applied SCH (a Di antagonist) and/or SUL (a D1 dopamine antagonist).
Whether the DA-mediated effects could be mimicked by the Di DA receptor agonist,
SKF, and/or the

Di

dopamine receptor agonist, QUIN also was examined. The

following protocol was used: 1) A spontaneously active VP/SI neuron was isolated and
stable pretreatment activity was obtained. 2) The agonist often was applied with an
ejection current of 100 or 120 nA for at least 1 min. 3) If this current produced a rate
change of greater than 203 of pretreatment activity that was reversible and reproducible,
the agonist was considered effective. When the current tested affected VP/SI neuronal
activity, often lower ejection currents were tested to determine if a current-response
relationship existed. If the maximal ejection current did not produce a rate change of
greater than 203 of control rates after being tested three consecutive times, the neuron
was considered insensitive to agonist. 4) After an agonist response was characterized,
either SCH or SUL was applied for at least 5 min prior to, and during the ejection of the
agonist. 5) An attenuation of the agonist-induced response of greater than 203 was
considered antagonism. The other antagonist was tested to verify that the agonist
response was receptor subtype specific.
To evaluate the responses of VP/SI neurons subsequent to electrical activation of
the VTNSNc and/or the AMN, the following protocol was used: 1) A spontaneously
active VP/SI neuron was isolated and pre-stimulation activity was monitored. 2)
VTAfSNc or AMN stimulation-evoked effects on VP/SI activity were determined using
a stimulation current that was shown in preliminary stimulation experiments to be
effective for these regions (i.e., 0.3 and 0.5 mA for VTNSNc and AMN, respectively).
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3) If an evoked response occurred in the VP/SI neuron (criteria for evoked response is
defined below), the procedure was repeated at lower stimulation current to determine the
response threshold. In contrast, if the VP/SI neuron was insensitive, currents up to 1.5
mA were used, after which an unresponsive neuron was considered insensitive, and
was not studied further. 4) Often the VP/SI neuron was assessed for sensitivity to
stimulation of the other brain region (for example, VTA/SNc stimulation would then be
followed by AMN stimulation) to determine if this VP/SI neuron expressed convergent
effects from these two brain regions. 5) DA was microiontophoretically-applied as
described above. If VP/SI neuronal activity was altered by DA, the SCH or SUL were
co-applied with DA. The antagonist ejection current necessary to attenuate the effects of
DA was used to evaluate the effectiveness on the VTA/SNc evoked VP/SI response. If
DA either had no effect on VP/SI activity or the antagonist (s) did not attenuate the DAinduced effect, the maximal ejection current that did not produce nonspecific membrane
effects (i.e., without reducing the amplitude or widening the duration of the action
potential) was used for antagonist ejection during the period of VTA/SNc stimulation.
6) During antagonist application, VTA/SNc stimulation was repeated using a stimulation
current that previously evoked a response on VP/SI neuronal activity that was clearly
above threshold but not the maximum effect observed (i.e., a stimulation current
producing approximately 503 of the maximal evoked response over the range of
stimulation currents tested for that neuron, or ECuso).
For experiment 2, which characterized the effects of VTA/SNc stimulation and
DA application on the AMN-evoked responses of VP/SI neurons, the following
protocol was used. 1) A spontaneously active VP/SI neuron was determined to be
sensitive to both VTA/SNc and AMN stimulation. 2) DA was microiontophoreticallyapplied during AMN stimulation using an ECuso for the AMN. 3) Subsequently, a train
of 10 pulses was delivered to the VTA/SNc, at stimulation currents at or below ECu50,
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100 ms prior to AMN stimulation to examine whether VTA/SNc stimulation could
attenuate the AMN-evoked VP/SI responses. A train of pulses was used for activating

VTA/SNc neurons, even though dopaminergic neurons in these regions fire with either
single spikes or in bursts of up to 10 pulses (Grace and Bunney, 1984a,b), since
biochemical studies indicate that the latter firing pattern elicits higher concentrations of
extracellular DA (Gonon, 1988; Gonon and Buda, 1985; Manley et al., 1992). In
addition, Yim and Mogenson (1982) observed that while both single or train stimulation
of the VT A is sufficient to evoke NA responses, only train stimulation is capable of
attenuating the NA excitatory responses to AMN stimulation.
A peristimulus rate histogram was generated for each sample of 128 stimulation
epochs, using a bin width of 2 ms. To test for significance in the evoked responses, the
mean number of action potentials (or counts) per bin occurring 80-100 ms before the
stimulation was determined and considered as the control interstimulus baseline. The
onset of an evoked response was delineated by the first of three consecutive bins with
counts that were greater than 1 standard deviation from the control mean, and the offset
was similarly defined by the first of three consecutive bins with a count within 1
standard deviation of the control mean (similar to methods used in Yim and Mogenson,
1983). Counts occurring within this time period were compared to the number of
counts occurring within this same time period after antagonist administration (or, in
experiment 2, the counts observed after AMN stimulation was compared for the same
boundary after dopamine application or VTA/SNc stimulation).
In some VP/SI neurons, drug application and/or stimulation of the VTA/SNc
prior to AMN stimulation (considered "treatment") altered the interstimulus baseline. To
compensate for any influence this baseline change might have had on action potential
occurrence during the evoked response period, a more stringent criterion was
determined by calculating an "expected value" (E) as described previously (Napier et al.,
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t983). E was defined as the number of action potentials (or counts) which would be

predicted to occur in the evoked period if the treatment did not alter interstimulus
baseline. To calculate E, the mean counts/bin occurring during the 80-100 ms period
prior to stimulation in the treatment sample (i.e., mean counts/bin of the interstimulus
baseline for the treatment) was divided by the mean counts/bin during the same period
of the interstimulus baseline in the control sample; this value was multiplied by the
number of counts occurring during the evoked period in the control sample (i.e., (mean
counts/bin for the treatment interstimulus + mean counts/bin for the control
interstimulus) X (mean counts/bin for the evoked response during control stimulation)).
Ethen was compared to the mean counts/bin actually observed during the evoked period
in the treatment sample. If the ratio of the observed counts to E was altered by greater
than 253, the treatment was considered effective.

Statistics
The magnitude of agonist-induced alterations of VP/SI firing rate is presented as
mean ± S.E.M. Comparisons of the magnitude of agonist-induced effects on VP/SI
neuronal activity for different DA agonists was assessed by an analysis of variance
(ANOV A) followed by a post-hoc Newman Keuls test. Paired

t

-tests are used to

assess differences in VP/SI neuronal activity induced by agonist application versus
agonist-induced effects with concomitant application of antagonists. Chi-square
analysis was used to detect changes in: 1) the distribution of VP/SI responses to
microiontophoretically-applied agonists, 2) the number of VT AfSNc-evoked VP/SI
responses that were sensitive or insensitive to the different antagonist treatments, and 3)
the number of AMN-evoked VP/SI responses that were attenuated or insensitive to DA
application versus VTNSNc stimulation. The criterion of significance for all statistical
tests was p < 0.05.
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Ujstoloeical Procedures
At the end of each experiment, the rat received an overdose of chloral hydrate
intravenously. The location of the last recording site was marked with fast green dye by
passing anionic current through the recording barrel of the electrode for 10-20 min. The
brain was removed, mounted, frozen and then cut with a microtome to locate the
electrode tracks as well as the fast green dye deposit. The brain sections were stained
with cresyl violet and the location of each recording site was determined using the fast
green spot and electrode tracks as reference points. The location of the stimulation sites
were assessed from the position of stimulation electrode tracks and reconstructed on
stereotaxic maps (according to Paxinos and Watson, 1986).

Results

Characteristics of Spontaneously Active VP/SI neurons
The data for this study were assessed for recordings of 233 neurons that were
histologically verified to be within the ventral pallidum/substantia innominata (VP/SI;
e.g., Fig. 10). All of the VP/SI neurons monitored were spontaneously active with a
mean discharge rate of 12.2 ± 0.63 spikes per second.

The most frequently

encountered recording demonstrated a firing pattern with a broad interspike interval
histogram denoting an irregular distribution of action potential occurrence intervals. Of
the total recorded neurons, 211 (91 3) displayed biphasic and 22 (93) had triphasic
action potentials. The mean duration of the action potentials was 1.2 ± 0.02 ms, with a
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Fig. 10. LOCATION OF RECORDING SITES IN THE VP OR THE SI, AND
STIMULATION SITES WITHIN THE AMN AND THE VTA OR SNc. (A, C, E) are
cresyl violet stained coronal sections that are representative photomicrographs of the
recording and stimulation sites. The arrows: in (A) indicates the position of the fast
green dye spot, in (B, E) indicate the position of the stimulating electrode. The right
column denotes individual recording and stimulation sites on maps redrawn from
Paxinos and Watson (1986). Many recording sites overlapped. Numbers in the left
comer indicate the distance (mm) from Bregma. Sections in (A, C, E) are denoted in the
~ 0:80, - 2.56, and - 5.30 maps in (B, D, F), respectively. In (B) , filled symbols
md1cate effective (EFF) and clear symbols indicate no change (NC) after stimulation of
VTA/SNc (diamonds), of AMN (stars), or convergence (circles). All VP/SI neurons
responded to at least one of the AMN stimulation currents tested.
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peak to peak amplitude of 338 ± 22 µV. One hundred ninety-eight recordings (853)
bad initially negative action potential waveforms, and the remaining 35 (153) had
initially positive waveforms. The recordings obtained in this study had similar
characteristics to those from previous studies on the effects of dopaminergic agents on
VP/SI firing rate (Maslowski and Napier, 1991a,b; Napier et al., 1991b; Napier, 1992).

Effects of D1 andfor D2 DA Receptor Activation on YPISI Neuronal
Firin&: Rate
In agreement with our previous studies (Napier and Potter, 1989; Napier et al.,
199lb), approximately half of the VP/SI neurons tested were sensitive to
microiontophoretic application of DA; responding with both rate suppressions and
excitations (Fig. 11 and Table 4). Since DA can mediate responses through both Di and

Di receptor subtypes, the Di DA agonist, SKF and the Di DA agonist, QUIN, were
applied onto VP/SI neurons to determine whether separate activation of either receptor
subtype was sufficient to affect VP/SI neuronal firing rate. VP/SI neurons responded to
SKF with rate suppressions more often and with a greater magnitude than to either DA
or QUIN (Table 4 and Table 5). Of the VP/SI neurons tested, 403 were inhibited by
SKF but only 153 were inhibited by QUIN. The reverse was observed for VP/SI
neuronal excitations, which occurred in only 73 of the neurons tested with SKF, but in
243 of the neurons tested with QUIN. In addition, of the 20 VP/SI neurons tested with
both agonists, 1 each demonstrated inhibition, excitation, or opposite effects to both
agonists; 5 were inhibited and 1 was excited only by SKF; 3 were excited only by
QUIN, and 8 were not affected by either of these compounds.
VP/SI neurons often were insensitive to QUIN, even when the concentration of
QUIN was twofold that of SKF (0.02 M versus 0.01 M, respectively). Higher QUIN
ejection currents used for unresponsive neurons frequently produced action potential
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Fi~. 11. CUMULATIVE RA TE HISTOGRAMS ILLUSTRATING THE EFFECTS
OF MICROIONTOPHORETIC APPLICATION OF DA, SKF AND QUN ON THE
FIRING RA TE OF VP/SI NEURONS. DA application induced both rate suppression
(A) or rate excitation (B). SKF application typically induced a decrease in VP/SI firing
rate that was current-dependent, but QUN application often did not alter activity (C).
~ugs were applied during the time indicated by the horizontal bars above the
histograms, and the magnitude of the ejection current is represented by number (in
nanoamps) above the bar.
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TABLE 4
DISTRIBUTIONa OF AGONIST-INDUCED RESPONSESb OF VP/SI NEURONS
Response Category
Decrease

Increase

No Effect

Dopamine
(0.2 M; 5 - 120 nA)
SKF38393c
(0.01 M; 10 - 120 nA)

21/93
(23 3)
12/30
(40 3)

26/93
(28 3)
2/30
(7 3)

46/93
(49 3)
16/30
(53 3)

Quinpirole
(0.01 - 0.02 M; 10- 120 nA)

5/33
(15 %)

8/33
(24 3)

20/33
(61 3)

Agonist

The ratio of the number of neurons affected by the agonist divided by the number
tested.

a

significant decrease or increase in ventral pallidal firing rate was defined as a
change of greater than 203 of baseline activity. No effect was determine as a change
of less than 203 of baseline activity with agonist ejection currents ~ 100 nA.

b A

c Chi-square analysis of the number of neurons in each response category following
the application of SKF38393 differed from that after dopamine or quinpirole
application (df = 2; x2 = 7.15 or 6.80, respectively; p < 0.05).
changes indicative of nonspecific 'membrane effects. In addition, the onset of SKFinduced inhibitory responses of VP/SI neurons occurred with significantly lower
ejection currents (N = 12, mean current: 40 ± 7 nA) than QUIN-induced excitations (N
= 8, mean current: 76 ± 15 nA; df = 18, t = -2.42, p < 0.05) or suppressions (N = 5,

mean current: 92 ± 14; df = 15, t = 3.75, p < 0.01).
Subsequent applications of the D1 receptor antagonist, SCH, or the Di receptor
antagonist, SUL, were used to assess whether the effects of DA on VP/SI neuronal
activity were mediated through D1 and/or Di receptors, as well as the receptor
specificity of SKF- and QUIN-mediated effects on VP/SI firing rate (Fig. 12).
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TABLE 5
MAGNITUDE OF AGONIST-INDUCED RESPONSES OF VENTRAL PALLIDAL
NEURONS
Agonist
(100 or 120 nA) a

Response Category (3 of control)

b

Decrease

Increase

SKF38393 (0.01 M)

59.79 ± 4.03
(N = 16)
38.77 ± 6.79 c
(N = 11)

145.22 ± 6.81
(N = 16)
147.30
(N = 1)

Quinpirole (0.01-0.02 M)
(N = 16)

69.63 ± 4.81
(N= 4)

133.70 ± 2.16
(N = 4)

Dopamine (0.2 M)

Data include only the response of neurons that were tested with the agonist at
maximum ejection current

a

b

Control (pretreatment) rate was standardized to 1003.

c The magnitude of the SKF38393-induced decrease differs from both dopamine and
quinpirole (ANOV A, df = 30; F = 6.15; p < 0.01, and significant Newman Keul's
post-hoc analysis, df = 1; q = 4.18 and 4.13; p < 0.05).

Suppression of VP neuronal activity by DA or SKF was attenuated by SCH (Fig. 12A).
In addition, SCH attenuated DA-induced excitations (Fig 12B). SKF-induced rate
excitations (N = 2) were not tested with antagonists. SCH did not antagonize QUINinduced rate inhibitions or excitations (Fig. 12A-B). SUL attenuated DA-induced rate
suppressions (Fig. 12C) but, in contrast to SCH, SUL application was not sufficient to
attenuate DA-mediated increases (Fig. 12D). Excitations induced by QUIN were
antagonized by SUL (Fig. 12D). Thus, DA-induced effects on VP/SI neuronal activity
were mediated through either Di or Di receptor subtypes, but SKF was specific for Di
receptor-mediated rate suppressions and QUIN was specific for Di receptor-mediated
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Fig. 12. BAR GRAPHS DEPICTING THE MAGNITUDE OF ATIENUA TION OF
DA-, SKF- AND QUN-MEDIA TED EFFECTS ON FIRING RA TE OF VP/SI
NEURONS BY CONCOMITANT APPLICATION OF SCH OR SUL. Only those
VP/SI neurons tested with both agonist and antagonist are included. DA- (0.2 M; 5-120
nA) and SKF- (0.01 M; 10-120 nA) induced VP/SJ rate suppressions (A) were
attenuated by SCH (0.01M;10-100 nA) application (Paired r - test, df = 6, r = -2.60,
p < 0.05 for DA vs. SCH; and df = 5, r = -5.02, p < 0.01 for SKF vs. SCH). (B)
SCH also attenuated DA- but not QUN-mediated VP/SI rate excitations (df = 10, r =
4.28, p < 0.01 for DA vs. SCH). SKF induced rate excitations in only 2 VP/SI
neurons that were not subsequently tested with antagonists. (C) SUL (0.02 M, 10-120
nA) attenuated DA-induced rate suppression of VP/SJ neurons (df = 13, t = -2.13, p <
0.05). (D) QUN-mediated excitations were antagonized by SUL (df = 3, t = 5.49, p <
0.05). Horizontal lines indicate control level of neuronal activity (considered as 100% ).
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rate excitations. Microiontophoretic application of vehicle solutions for agonists (as
well as antagonists) did not alter the firing rate of VP/SI neurons (N = 10; data not
shown).

Responses of VP/SI Neurons to Sin&le Pulse Stimulation of the Midbrain

-

Jl.ppaminer&ic Re&ion
Figure 10 illustrates the location of the VP/SI neurons assessed for sensitivity to
stimulation of VTA/SNc (Fig. IOA,B), and the stimulation sites within these midbrain
dopaminergic regions (Fig. IOE,F). Of 138 VP/SI neurons tested, 135 were sensitive
to midbrain stimulation of the ventral tegmental area VTA (N = 82) or the substantia
nigra pars compacta SNc (N = 53). Stimulation of the VTA or the SNc produced
similar number and types (i.e., inhibition or excitation) of evoked VP/SI responses, and
the distribution onset latencies of each response type overlapped. Therefore, the results
of activating these brain regions were combined. Although some VP/SI neurons
responded to VTA/SNc stimulation with simple inhibition (Figs. 13A-C, 14, 15, 16) or
excitation, 603 the sensitive VP/SI neurons exhibited a complex sequence of evoked
responses (Fig. 13D-F and Table 6). The distribution of the latencies of the inhibitory
responses was bimodal, with one peak in the range of 4 to 6 ms, and the other from 15
to 21 ms. The distribution of the latencies of the excitatory responses was also bimodal,
with one peak in the range of 4 to 6 ms, and the other from 28 to 30 ms. The most
frequently observed response was an inhibition with a range of onset latencies from 2 to
12 ms (Fig. 13A-C and Table 6).

Since these distributions may indicate the

involvement of distinct midbrain efferents to the VP/SI for the evoked response
observed, the response were categorized into short(~ 12 ms) or long(> 12 ms) latency,
as well as inhibitions or excitations (Table 6).
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The effects of VTA/SNc stimulation on VP/SI neuronal activity were assessed
further in 111 VP/SI neurons to determine if there was a relationship between the
characteristics of the evoked response and increasing stimulation intensity to the
VTA/SNc. The duration of the VP/SI inhibitory responses was augmented by
increasing the stimulation intensity to the VTA/SNc (Fig. 14A-C) suggesting the
recruitment of additional inhibitory inputs. Similarly, VP/SI neurons that displayed an
initial excitatory evoked response, often exhibited a secondary inhibition whose duration
was augmented by increasing the stimulation currents. In 7 VP/SI neurons tested with

VTA/SNc stimulation, currents up to 0.8 mA appeared to be restricted to a distance of 1
mm, since VP/SI evoked responses were terminated when the stimulating electrode was
moved 1 mm from the "active site", and greatly attenuated when moved 0.5 mm away
(Fig. 15).

DA Receptor Subtypes Involved with VP/SI Responses to VT A/SNc
Stimulation
VP/SI responses to VTA/SNc stimulation often were mimicked by the effects of
microiontophoretic application of DA on the firing rate of VP/SI neurons. Of the VP/SI
neurons that responded to both VTA/SNc stimulation and microiontophoretic DA,
1003 of the VTA/SNc-evoked inhibitory VP/SI responses also demonstrated DAinduced rate suppressions (N = 13), and 603 of VTA/SNc-evoked excitatory VP/SI
responses, demonstrated DA-induced rate excitations (N = 15), and the remaining 403
displayed DA-induced rate inhibitions.
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Fig. 13.
EXAMPLES OF VP/SI RESPONSES TO SINGLE PULSE
STIMULATION OF THE VTA. The most frequent response to VTA/SNc stimulation
was a short latency inhibition depicted by a VP/SI neuron in (A-C). VTA stimulation
also evoked short latency excitation in the activity of second VP/SI neuron in (D-F).
Oscilloscope traces, composed of 10 superimposed sweeps (A, D); raster stepper
recordings composed of 128 consecutive sweeps (B, E); and peristimulus rate
histograms (C, F) of the same 128 sweeps as in B and E, respectively. Triangle
indicates the stimulus artifact. Connected arrows indicate the onset and offset of VP/SI
evoked responses. Vertical bars in (C and F) indicate the number of action potentials
per 2 ms time bin. Stimulation parameters: 0.1 ms; 1 Hz; A-C. 0.5 mA; D-F. 0.1 mA.
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Table 6
SUMMARY OF VENTRAL PALUDAL EVOKED RESPONSES TO
STIMULATION OF THE VENTRAL TEGMENTAL AREA/SUBSTANTIA NIGRA
PARS COMPACTA AND AMYGDALA
Response Category a
Short
Long
Latency
Latency
Excitation
Inhibition
(> 12 ms)
(~ 12 ms)

Region
Stimulated

Number of
Short
Neurons
Latency
Sensitive to Inhibition
Stimulation b (~ 12 ms)

VTA/SNc

135/138

80/135
(593)

41/135
(303)

70/135
(523)

70/135
(523)

86/ 86

39/ 86
(453)

42/ 86
(493)

67/ 86
(783)

52/ 86
(603)

AMN

Long
Latency
Excitation
(>12 ms)

a The response categories were defined by the latency in ms to the onset of a
particular evoked response, as described in the Methods.
b Only 3 VP/SI neurons were insensitive to VTA/SNc stimulation (stimulation

current range: 0.5 to 1 mA) and were not included in the table. Sixty percent of
VP/SI neurons responding to VTA/SNc stimulation and 803 responding to AMN
stimulation exhibited a complex response sequence consisting of more than one
evoked response. Thus, the sum of the percents is greater than 100, since the
occurrence of each response is indicated in the numerator and each neuron tested is
indicated in the denominator.
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Fig. 14. AN EXAMPLE OF A VTA STIMULATION CURRENT-DEPENDENT
INHIBITORY RESPONSE JN THE SAME VP/SI NEURON. As the current used to
stimulate the VTA (0.1 ms, 1 Hz) was increased from 0.1 mA to 0.3 mA, a short
latency inhibitory response was evoked in the VP/SI neuronal activity (A-B). With an
increase of stimulation current to 0.5 mA the duration of the short latency inhibitory
response increased to greater than 100 ms (C). Triangles indicate the stimulus artifact,
the arrows depict the onset and offset of the VP/SI evoked responses. The vertical bar
indicates the number of action potentials per 2 ms time bin.
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15. RELATION SHIP BETWEEN THE LOCATION OF THE MID BRAIN
STIMULATING ELECTRODE AND THE EVOKED VP/SI RESPONSE. VT A
stimulation did not alter firing when the stimulating electrode was 1 mm above the active
site within the VTA (A), but produced a slight inhibitory response when the stimulating
electrode was located within 0.5 mm of this site on the periphery of the VT A (B).
When the stimulating electrode was placed near the center of the VTA a VP/SI long
latency inhibitory response of about 30 ms duration was evoked (C). The number in the
upper left comer of the stereotaxic map represents the distance from Bregma. Triangles
indicate the stimulus artifact, and the connected arrows depict the onset and offset of the
inhibitory response to stimulation of the center of the VT A area (C). The vertical bar on
the peristimulus histograms indicates the number of action potentials per 2 ms bin.
Stimulation parameters were 0.1 ms; 1 Hz; 0.8 mA.
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To determine the receptor subtype (s) involved in VP/SI responses to VTNSNc
stimulation, SCH or SUL was microiontophoretically applied within the local milieu of
the recorded VP/SI neuron during the period of VTA/SNc stimulation. Figure 16
illustrates a typical VP/SI response to VTNSNc stimulation (short latency inhibition),
an attenuation by SCH, as well as the less frequently observed, and more modest
attenuation by SUL. Seventeen of 20 evoked responses attenuated by SUL also were
antagonized by SCH, but simultaneous application of the antagonists did not induce a
greater magnitude of attenuation. Evoked responses that were not attenuated by either
antagonist alone could not be attenuated by concurrent application of the antagonists
(Table 7).

However, intravenous administration of the D1/D2 DA antagonist,

flupentixol was sufficient to attenuate the VP/SI short latency inhibitory responses in all
4 neurons tested (Table 7). In addition to the short latency inhibitions, both short and
long latency excitations evoked in the VP/SI were attenuated by SCH or by SUL (Table

7).

Effects of VP/SI Neurons to Sin&le Pulse Stimulation of the AMN
Figure 10 illustrates the location of VP/SI neurons affected by stimulating the
AMN (Fig. lOA,B). Most of the AMN stimulation sites were within the basolateral
nucleus (Fig. lOC,D), which evoked VP/SI responses with the lowest stimulation
intensity. The evoked responses were not antidromically mediated since the criteria of
constant onset latency and ability to follow pulse-pair stimulation at high frequency was
not fulfilled (Lipiski, 1981). The distribution of latencies of evoked VP/SI inhibitory
responses was bimodal, with one peak between 2 to 6 ms, and the other from 16 to 18
ms. The distribution of latencies of evoked VP/SI excitatory responses also was
bimodal, with one peak occurring between 4 to 12 ms, and the other from 16 to 18 ms.
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Fig. 16.
PERISTIMULUS HISTOGRAMS OF A SHORT LATENCY
INHIBITORY RESPONSE IN A VP/SI NEURON TO VTA STIMULATION (0.1 ms,
1 Hz), AND THE ATTENUATING EFFECTS OF CONCURRENT
MICROIONTOPHORETIC APPLICATION OF SCH OR SUL. (A) VTA stimulation
produced an inhibitory response of 2 ms latency and 14 ms duration for this VP/SI
neuron (indicated by arrows). SCH antagonized this inhibitory response (B), while
SUL application only produced a slight attenuation (C). The vertical bar in (A) indicates
the number of action potentials per 2 ms bin, and triangles indicate the stimulus artifact.
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Table 7
OOPAMINEANTAGONIST-INDUCEDATTENUATION OFVENTRAL
PALLIDAL RESPONSES EVOKED BY STIMULATION OF Tiffi VENTRAL
TEGMENTALARENSUBSTANTIA NIGRA PARS COMPACTA

Antagonist

Response Category a
Short latency Short latency Long latency Long latency
Inhibition
Excitation
Inhibition
Excitation
(s 12 ms)
(> 12 ms)
(> 12 ms)
(S 12 ms)

SCH23390
(10-100 nA)

16/23
(703)

31 8
(383)

6/10
(603)

7110
(703)

Sulpiride
(5-100 nA)

3111
(273)

9114
(643)

7113
(543)

SCH23390/Sulpiride
(10-100 nA)

10/22
(453)
31 8 b
(383)

Flupentixol
(0.05-4 mg/kg, i.v.) c

4/ 4
(1003)

The response category was defined as the ratio of the evoked responses displaying a
203 attenuation to the number of responses tested with the antagonist.

a

These 3 evoked responses also were attenuated by individually applied sulpiride or
SCH23390.

b

c Of the 4 neurons tested, 1 responded to dose of 0.05, another to 2.0, and the
remaining 2 neurons responded to 4 mg/kg, i. v. of the antagonist.

Thus, the VP/SI responses (both excitatory and inhibitory) were categorized as short (s
12 ms) or long(> 12 ms) latency (Table 7). Although some VP/SI neurons displayed
only one type of evoked response (Fig. 17A-C), the most frequent effect of AMN
stimulation was a complex sequence of evoked VP/SI responses (Figs. 17D-F, 18,
19B). The most often observed AMN-evoked VP/SI response category was a long
latency inhibition (Fig. 18, 19B, 20A; Table 7). For many VP/SI neurons tested,
increasing the stimulation intensity evoked more complex response patterns (Fig. 18),
rather than an increase in response duration observed with VTAfSNc activation.
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Modulation of VP/SI Responses to AMN Stimulation by Activatin2 the
VTA/SNc and Microiontophoretically Applyin2 DA
The majority of VP/SI neurons that responded to AMN stimulation also
responded to activation of the VTA/SNc (Fig. lOB). Of sixty-one VP/SI neurons that
displayed short latency effects to AMN stimulation, 923 also demonstrated short
latency VP/SI responses to VTA/SNc, suggesting extensive convergence of these to
inputs within the VP/SI (e.g., Fig. 19). Similarly, of 48 VP/SI neurons with long
latency effects evoked by AMN stimulation, 793 also exhibited short latency effects to
VTA/SNc stimulation, suggesting that VTA/SNc may modulate, at the level of the
VP/SI, the polysynaptically-mediated effects of AMN stimulation. To determine if
VTA/SNc can influence AMN-evoked VP/SI neuronal activity, the effects of both
endogenous DA (presumably released through VTA/SNc stimulation) and exogenouslyapplied DA (microiontophoretic) were examined. To assess the modulatory effects of
activating the VTA/SNc with a train of 10 pulses on AMN-evoked responses of VP/SI
neurons, a VTA/SNc stimulation current that minimally evoked (e.g., Fig. 19C-D), or
did not evoke (Fig. 20B-C), a VP/SI response was employed (see Methods).
Figures 19 and 20 illustrate DA-mediated attenuation of a VP/SI long latency
inhibitory response to AMN stimulation by prior stimulation of the VTA and by
microiontophoretically-applied DA (Fig. 19E). The long latency excitatory response of
this neuron also was diminished by VTA stimulation and DA (Fig. 19C-E). Modulation
of the AMN-evoked VP/SI response by prior VTA/SNc activation was observed even
when VTA/SNc stimulation did not evoke a VP/SI response (Fig. 20B-C). Likewise,
microiontophoretic application of DA, even at ejection currents that did not affect
baseline interstimulus rate (Fig. 19B, E), effectively modified the AMN-evoked VP/SI
response similar to the attenuation produced by VTA/SNc stimulation (Fig. 19D, E).
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Fig. 17. TWO VP/SI NEURONAL RESPONSE SEQUENCES EVOKED BY
SINGLE PULSE STIMULATION OF THE AMN (0.1 ms, 1 Hz). A short latency
inhibition is illustrated by one VP/SI neuron in (A-C), and a short latency excitation
represented by another VP/SI neuron in (D-F) Oscilloscope traces (A, D), composed of
IO superimposed sweeps, il1ustrating the VP/SI evoked responses. A faster sweep
speed was used in (D) to more clearly illustrate the onset of the short latency excitation.
Raster stepper recordings in (B, E) are composed of 128 consecutive sweeps of evoked
VP/SI activity;. peristimulus rate histograms in (C, F) are of the same 128 sweeps as in
Band E, respectively. The vertica1 bar in (A) indicates the number of action potentia1s
per 2 ms bin; triangles indicate the stimulus artifact and connected arrows depicted the
onset and offset of VP/SI evoked responses.
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Fig. 18. AMN STIMULATION CURRENT-DEPENDENT INCREASE OF THE
COMPLEXITY OF RESPONSES EVOKED IN A VP/SI NEURON. As the current
used to stimulate the AMN (0.1 ms, 1 Hz) was increased from 0.3 mA to 0.5 mA, the
long latency inhibitory response evoked in the VP/SI neuronal activity was preceded by
a short latency excitation (A-B). With a further increase of stimulation current to 0.8
mA, the duration of the long latency inhibitory response increased from 28 to about 40
ms (C). Triangles indicate the stimulus artifact, the connected arrows depict the onset
and offset of the VP/SI evoked responses. The vertical bar indicates the number of
action potentials per 2 ms time bins.

107

A

VTA0.3mA
1

:1

I
I

...

~

B

c

SOmsec

.Jll~...u...Jt.J

-

~

#1

AMN 0.3mA

#10

#2

ci

~

...

~

D

~
...,

#1

AMN 0.3mA

0

ci

<

>

E

~
C?

ci

z

~

<

...

~

Fig. 19. CONVERGENCE OF VT A AND AMN INFLUENCES WITHIN THE
VP/SI, AND MODULATION OF AMN STIMULATION-INDUCED VP/SI
RESPONSES BY VTA STIMULATION AND BY DA. VTA stimulation (0.1ms,1
Hz) produced a short latency inhibitory response (A). AMN stimulation (0.1 ms, 1 Hz)
produced a short latency inhibitory, a long latency excitatory and a long latency
inhibitory response on the same neuron (B). A train of 10 pulses (0.1 ms, 0.1 or 0.05
mA) at IO Hz to the VTA evoked a VP/SI short latency inhibitory response that
attenuated the long latency excitatory and inhibitory responses to AMN stimulation
(C,D). The short latency inhibition evoked by the AMN was potentiated by VT A
stimulation in this neuron, although this phenomenon was not typically observed.
Microiontophorectically-applied DA (0.2 M; in E) mimicked the attenuation of AMNevoked VP/SI responses produced by the 0.05 mA VT A stimulation current in (D).
Triangles indicate the stimulus artifacts, and connected arrows indicate the onset and
offset of the evoked responses. The vertical bar represents the number of action
potentials per 2 ms bin. In (C,D) the numbers 1, 2, 10 indicate the stimulus artifact for
the first, second and last pulses of a 10 pulse train delivered to the VTA.

108

AMN 0.2mA

A

:1 .._...lllimi~--.JWUIUlmiil•
• •----•

SOmsec

B

c

c(

E #1

#2

#10

AMN 0.2mA

I()

0

ci
c(

>
*'

Fig. 20. MODULATION OF AN AMN-EVOKED VP/SI RESPONSE BY PRIOR
STIMULATION OF THE VTA WITH A SUBTHRESHOLD CURRENT. AMN
stimulation (0.1 ms, 1 Hz) induced a long latency inhibitory VP/SI response (A).
Stimulation of the VT A with a train of 10 pulses at 10 Hz was below the threshold for
evoking activity of this VP/SI neuron (B). However, train stimulation of the VTA I00
ms prior to AMN stimulation was sufficient to attenuate the AMN-evoked VP/SI long
latency inhibitory response. Triangles indicate the stimulus artifacts, and connected
arrows indicate the onset and offset of the VP/SI response evoked by AMN stimulation
as shown in (A). The vertical bar represents the number of action potentials per 2 ms
bin.
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This example concurs with the similar effects of DA application and VTA/SNc
stimulation on each of the AMN-evoked VP/SI response categories (Table 8). Thus, the
modulatory effects of VT A/SNc stimulation on AMN-induced VP/SI responses may
involve DA.

Table 8
ATTENUATION OF VENTRAL PAWDAL RESPONSES TO AMYGDALA
STIMULATION BY EXOGENOUS OR ENDOGENOUS DOPAMINE

Physiological
Antagonist

Response Category a
Short Latency Short Latency Long Latency Long Latency
Inhibition
Excitation
Inhibition
Excitation
(~ 12 ms)
(~ 12 ms)
(> 12 ms)
(> 12 ms)

Dopamine
(5-120 nA)

7/11
(643)

7/15
(473)

20/25
(803)

5/13
(383)

VTA/SNc Stimulation
(0.05-0.8 mA)

11/13
(853)

10/18
(563)

26/33
(783)

11119
(583)

a Indicates the number of VP/SI evoked responses to amygdala stimulation that were
attenuated by the physiological antagonist divided by the number of amygdala-evoked
responses tested. Chi-square analysis comparing the response to dopamine versus
VTA/SNc stimulation for each response category was not significantly different.

Discussion

Contribution of DA Receptor Subtypes to DA-mediated Effects on VP/SI
Neuronal Acthity
The present study demonstrated that microiontophoresis of DA alters the firing
rate of VP/SI neurons, producing both inhibitions and excitations. Previous studies
also indicate that DA can suppress or excite VP/SI neuronal activity, and collectively it
appears that the predominant effect of DA is a current-dependent decrease in firing rate
(Napier and Potter, 1989; Napier et al., 199lb). DA-induced changes in the activity of
110

yp/SI neurons are antagonized by systemically administered SCH or haloperidol
(Napier et al., 199lb), suggesting an involvement of both Di and Di receptor subtypes.
Similar results are observed following the systemic administration of the D1/Di agonist,
apomorphine, which also induces rate suppressions and excitations that are sensitive to
haloperidol (Napier et al., 199lb), SCH or SUL (Maslowski and Napier, 199lb). The
present data concur that the DA-induced inhibitions involve the activation of both D1 and

Dz DA receptors within the VP/SI, since locally-applied SCH or SUL antagonized the
inhibitions. However, DA-induced rate excitations were antagonized by SCH but not
by SUL, suggesting that the excitations were mediated through activation of the D1
receptor subtype within the VP/SI. When the selective D1 and Di antagonists were used
to determine the contribution of D1 and

Di receptors to DA-induced changes of VP/SI

neuronal activity, inhibitory effects of DA were mediated by D1 or Di receptor activation
within the VP/SI; moreover, D1 receptor activation also mediated the excitatory effects.
The present results also demonstrated that activation of either the D1 or the Di
receptor within the VP/SI was sufficient to induce VP/SI rate changes. Forty-seven
percent of VP/SI neurons tested were sensitive to SKF application, and the activity in
86% of these neurons was suppressed. This effect was attenuated by SCH but not by
SUL, confirming that SKF-induced rate suppressions were mediated through the
activation of the D1 receptor subtype. In contrast, QUIN induced slightly more rate
excitations than rate inhibitions. The excitations were antagonized by SUL but not by
SCH, verifying the involvement of the Di receptor in this response. Di-mediated
increases in VP/SI activity induced by QUIN appear to be independent of DA-induced
excitations, since the latter were not antagonized by SUL. These results suggest that D1
and Di agonist applications within the VP/SI have opposing effects on VP/SI firing rate,
since activating D1 plus Di receptors with DA induces rate suppressions whose
magnitude is less than activating the D1 receptor with SKF.
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Oppositional VP/SI responses also are obtained with systemic administration of
SKF and QUIN, however, the direction of the responses is reversed such that
intravenous SKF increases and QUIN decreases firing rate (Maslowski and Napier,
. t99la).

This data, together with the observation from the present study that

polysynaptically-mediated effects were produced by VTA/SNc stimulation, suggest the
possibility that VP/SI responses to systemically administered DA agonists reflect
changes in the activity of dopaminoceptive regions that are afferent to the VP/SI.
Previous studies support this hypothesis since inactivation of the AMN produced by
procaine microinjections reduce the number of VP/SI neurons sensitive to systemically
administered SKF (Napier, 1992).

Similarities between the Effects of Endoienous and Exo2enous DA on
the Spontaneous Activity of VP/SI Neurons
With the demonstration that VTA/SNc stimulation alters the activity of VP/SI
neurons, the present results provide a function for anatomical reports of dopaminergic
innervation of the VP/SI from the VTA (Grove, 1988; Haring and Wang, 1986; Jones
and Cuello, 1989; Russchen et al., 1985; Semba et al., 1988; Zaborszky, 1989), and
the SNc (Fallon and Moore, 1978; Haring and Wang, 1986; Jones and Cuello, 1989;
Martinez-Murillo et al., 1988; Russchen et al., 1985; Semba et al., 1988; Zaborszky,
1989) to the VP/SI, and concurs with previous findings that VP/SI neurons often are
inhibited by SNc stimulation (Napier et al., 199la). VP/SI neuronal activity was
similarly altered by VTA and SNc stimulation, which implies that limbic (VTA) and
extrapyramidal motor (SNc) pathways both influence the output of VP/SI neurons.
Many of the VTA/SNc evoked responses of VP/SI neurons exhibited latencies
less than 12 ms. The distance from the VTA/SNc to the VP/SI (as calculated from
stereotaxic coordinates) is approximately 5-6 mm. With a conduction velocity of
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dopaminergic fibers of approximately 0.5 mis (Guyenet and Aghajanian, 1978; Yim and
Mogenson, 1980) and a synaptic delay accounting for another 0.5 ms (Kuffler et al.,
1984), the onset of monosynaptic DA-mediated effects can occur within 12 ms. In
VP/SI neurons with slower firing rates, the onset of evoked responses appears to occur
immediately after the stimulus artifact because the interspike interval of the spontaneous
activity was longer than the delay for orthodromic conduction, whereas neurons with
faster firing rates displayed action potentials prior to the evoked response that were not
driven by the stimulus. Some of the short latency VP/SI responses may be mediated by
dopaminergic neurons from the VTA/SNc. This conclusion is supported by evidence
that these short latency responses were attenuated by intra-VP/SI application of DA
antagonists. Thus, the results indicate that some of the VTA/SNc inputs to the VP/SI
are monosynaptic and dopaminergic.
According to criteria established by Werman ( 1966) for potential
neurotransmitters, exogenously-applied DA should mimic the response to evoking the
endogenous system. The present results fulfill this criterion, since all of the inhibitory,
and 603 of the excitatory VP/SI responses produced by VTA/SNc stimulation were
mimicked by microiontophoretic applications of DA within the VP/SI. In addition,
SCH or SUL applied within the VP/SI antagonized the evoked responses, as well as
DA-induced VP/SI rate suppressions. Thus, endogenous DA is released within the
VP/SI during electrical stimulation of the VTA/SNc, and DA then alters the spontaneous
activity of this region through the activation of Di or Di receptor subtypes.
VT A/SNc stimulation also evoked VP/SI responses that exhibited long onset
latencies characteristic of polysynaptic transmission. These polysynaptic events may be
mediated through interneurons within the VP/SI or through afferents to this brain
region. Afferents to the VP/SI, including the NA and AMN, receive midbrain
dopaminergic innervation (Fallon and Moore, 1978; Fallon et al., 1978). Thus,
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VTA/SNc evoked responses of the VP/SI may be mediated indirectly through alterations
in neuronal activity of these systems. NA neurons display a variety of responses to
VTA stimulation, and 503 of the responses are attenuated by systemic administration of
the DA antagonist, haloperidol (Yim and Mogenson, 1982). Since microinjections of
DA into the NA excites VP/SI neurons (Yang and Mogenson, 1989), it is possible that
VT A stimulation-induced, endogenous release of DA affects VP/SI neuronal activity
indirectly through altered output from NA afferents. The effects on VP/SI neuronal
activity of DA receptor stimulation within the AMN are unknown. Since long latency
responses of VP/SI neurons to VTA/SNc stimulation were readily attenuated by intraVP/SI application of Di or Di antagonists, VTA/SNc stimulation-evoked responses of
VP/SI neurons, regardless of their monosynaptic or polysynaptic nature, are under DA
modulatory control at the level of the VP/SI.

Effects of Endo1enous and Exo1enous DA on AMN-evoked Responses
of VP/SI Neurons
VP/SI is site of convergence for midbrain and AMN inputs, where 56 of 61
VP/SI neurons tested (923) displayed short latency (monosynaptic) evoked responses
to stimulation of both regions. This extensive convergence may allow the VTAfSNc to
modulate AMN-evoked VP/SI responses, since 853 of the AMN-evoked short latency
inhibitory, and 563 of the short latency excitatory, VP/SI responses were attenuated by
prior stimulation of the VTAfSNc. Activation of these midbrain areas can function as a
physiological antagonist of the monosynaptic AMN input to the VP/SI. Similarly, intraVP/SI DA application attenuated 643 of the inhibitory, and 473 of the excitatory, short
latency VP/SI responses to AMN stimulation, suggesting that DA may be the transmitter
involved. Thus, VTAfSNc dopaminergic efferents to the VP/SI modulate the output of

A.MN efferents to the VP/SI.
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AMN stimulation also evoked long latency inhibitory and excitatory VP/SI
responses, the long latency inhibitions being the most frequently observed of all AMNevoked effects. Long latency inhibitory effects can be produced via the NA, since Yim
and Mogenson (1983) observed that procaine-induced inactivation of the NA attenuates
54 % of the AMN-evoked long latency inhibitions of VP/SI neurons. The AMN-evoked
long latency inhibitory responses of VP/SI neurons also are attenuated by the VTA
stimulation (Yim and Mogenson, 1983; present study). DA release within the NA is
thought to mediate the VTA stimulation-induced attenuation of AMN-evoked VP/SI
responses, since d-amphetamine injected within the NA mimics this effect in 54 % of the
VP/SI neurons (Yim and Mogenson, 1983). The present study indicates that activating
the VTA/SNc can modify the AMN-evoked long latency responses (either inhibitions or
excitations) within the VP/SI, since 38 of 48 VP/SI neurons (79%) with AMN-evoked
long latency responses, also were affected monosynaptically by VTA/SNc stimulation.
Likewise, 80% of the long latency inhibitory, and 38% of the long latency excitatory
VP/SI responses evoked by AMN stimulation were attenuated by intra-VP/SI DA
application. Thus, the attenuating effects of VT A/SNc stimulation on long latency
inhibitions (and excitations) of VP/SI activity evoked by AMN stimulation may be
mediated through DA release within the VP/SI.

Functional Si2nificance of the Conver2ence of VT A/SNc Dopaminer2ic
and AMN Limbic Influences within the YP/SI
The AMN has been implicated in a number of functions, including modulation
of hormonal secretion and autonomic activity, as well as defensive behaviors (Carlsen,
1989; Gloor, 1978; Nakano et al., 1987). Electrical stimulation of the AMN alters the
activity of VP/SI neurons (Tsai et al., 1989; Yim and Mogenson, 1983; and the present
study). VP/SI responses to AMN stimulation may involve transmission of limbic
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influences from the AMN to the VP/SI. With the changes in VP/SI neuronal activity,
the output of these neurons to its targets also may be altered. This hypothesis is
supported by the finding that more than two-thirds of the VP/SI neurons that are
antidromically activated by stimulation of the pedunculopontine nucleus exhibit AMNevoked excitatory responses (Tsai et al., 1989). The excitatory effects of AMN
stimulation on the VP/SI can be transmitted to the pedunculopontine nucleus altering the
activity of this nucleus. Thus, AMN afferents to the VP/SI may contribute limbic
influences on the VP/SI efferents to brainstem regions associated with locomotor
activity. The attenuation of AMN-evoked VP/SI neuronal responses by VTAfSNc and
DA suggests that DA modulates the effectiveness of AMN limbic influences on VP/SI
activity.
The role of the VP/SI in the ventral striatopallidal system proposed in previous
studies (for review see Mogenson and Yang, 1991) was as an intermediary between NA
outputs, that are extensively modified by limbic inputs from the AMN and
hippocampus, and the mesencephalic locomotor region. This system is modulated
further by midbrain dopaminergic neurons to the NA which can activate VP/SI neurons,
since 1) intra-NA DA application increases the spontaneous activity of VP/SI neurons
(Yang and Mogenson, 1989), and 2) intra-NA d-amphetamine attenuates the VP/SI
inhibitory responses to AMN stimulation (Yim and Mogenson, 1983). A significant
finding of the present study is that the VP/SI is affected monosynaptically by VTAfSNc
stimulation, suggesting the potential for modulation "downstream" of NA disinhibitory
effects on VP/SI activity. AMN-evoked VP/SI activity is also modulated at the level of
the VP/SI by VTAfSNc stimulation and DA. These results expand the functions of the
VP/SI from a relay site for NA output to an active processing center of AMN and
VTNSNc inputs beyond the level of the NA.
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In conclusion, DA appears to be intimately involved in modulating processes
mediated by the ventral striatopallidal system. Extensive findings indicate that the
ventral striatopallidal pathway participates in consolidating the information from the
limbic system and the extrapyramidal motor system (Mogenson et al., 1980, 1988;
Heimer et al., 1982; Heimer and Alheid, 1991; Mogenson and Yang, 1991). These
reviews are complemented by recent studies revealing that the VP/SI "may be an
important site in the processing of the reinforcing effects of drugs" and that the NA to
VP/SI innervation "may be a common pathway for both stimulant and opiate
reinforcement" (Koob et al., 1991). Considering the multifarious effects of DA on
neuronal activity and behavior mediated through many brain regions, including the
ventral striatopallidal system, the actions of DA are currently undergoing reevaluation
(Alexander and Crutcher, 1990; Graybiel, 1990; Smith and Bolam, 1990; Le Moal and
Simon, 1991). DA is thought to act as a neuromodulator to set the gain, or level of
output rather than activating or inactivating the ventral striatopallidal system (Graybiel,
1990). The affects of DA within a brain region may be determined by the neuronal
activity and functions encompassed by that brain region (Le Moal and Simon, 1991).
Previous studies demonstrate that DA within the NA attenuates the effects of AMN
stimulation on the neuronal activity of the NA (Yim and Mogenson, 1982). In the
present study, DA application within the VP/SI modulated the effectiveness of AMN
stimulation to alter the activity of VP/SI neurons. Thus, dopaminergic innervation at
each level of the circuit could then serve as a dynamic modulator of specific behaviors
elicited by ventral striatopallidal system via its efferent innervation.
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CHAPTER VI
GENERAL DISCUSSION

Role of the D1 and the D2 Receptor Subtypes
Introduction
Previous studies have provided adequate anatomical, biochemical and functional
evidence that the VP/SI is a dopaminoceptive brain region. The results presented in this
dissertation indicate that the effects of DA on VP/SI activity can be mediated through
separate stimulation of the D1 or the D2 receptor subtype. In the first experiment,
systemic administration of selective D1 or Di agonists was sufficient to elicit changes in
VP/SI neuronal activity. These changes were subsequently attenuated by administration
of the antagonist that is selective for the stimulated receptor subtype. It was also
demonstrated that individual activation of the D1 or the D2 receptor subtypes had
opposing influences on the neuronal activity of the VP/SI.
The opposite effects of D1 and Di receptor activation on VP/SI neuronal activity
differentiates this brain region from the morphologically similar GP (Heimer and
Wilson, 1975). VP/SI neurons appear to be more sensitive than GP neurons to
systemic administration of either QUIN or SKF, since: 1) more VP/SI neurons were
responsive, and 2) responses were observed at lower doses of these agonists (compare
results of Chapter III with Carlson et al., 1988). However, the magnitude of the rate
increases induced by SKF in either brain region is similar (Chapter III; Carlson et al.,
1988). In contrast to the effects of D1 receptor activation in VP/SI, the predominant
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response to Dz receptor activation was suppression of VP/SI activity (Chapter III), and
stimulation of GP activity (Carlson et aL, 1987a; 1988).
The difference between the VP/SI and the GP is obvious in the independent
effects (and oppositional effects) of SKF and QUIN on VP/SI activity versus the
synergistic effects of these same agonists on GP activity. The predominant difference
between these brain regions is their sensitivity to Dt receptor activation, which may be
explained, in part, by studies demonstrating greater numbers of Di binding sites within
the VP/SI as compared to the GP (Bardo and Hammer, 1991; Beckstead et al., 1988;
Boyson et al., 1986; Dawson et al., 1986a, 1986b; Mansour et al., 1990; Napier et al.,
199la; Richfield et al., 1987; Savasta et al., 1986). Recent studies using polyclonal
antbodies against the Di receptor indicate that Di receptors are heavily concentrated
within limbic regions including the VP/SI (Huang et al., 1992).
There is also evidence from molecular biological studies that the VP/SI has postsynaptic (Fremeau et al., 1991; Mengod et al., 1991; Weiner et al., 1991), whereas the
GP does not appear to have post-synaptic Dt receptors. In addition, the Dl postsynaptic receptors within the VP/SI may also be independent of ACy and cyclic AMP
generation. Thus, DA or Di agonists can induce Di-mediated responses within the
VP/SI by activating both pre- and post-synaptic receptors, but only by activating presynaptic receptors within the GP. The differences in the amount and location of Di
receptors, along with the possibility of activating alternative second messenger systems,
may be responsible for the disparity of DA agonist effects on VP/SI versus GP activity.
The second set of experiments confirmed that the actions of the nonselective DA
agonist, APO, were mediated through both Di and

Dz receptor

subtypes, and that

stimulation of either subtype is sufficient to influence the neuronal activity of the VP/SI.
Alterations of VP/SI neuronal activity to a single dose of APO did not exhibit a
predominant direction; approximately 40% of the tested neurons were excited, another
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40% were inhibited, and the rest were insensitive to the agonist. These results are
similar to the APO-induced effects on the neuronal activity of the SNr in rats that have
not been treated with the catecholaminergic toxin, 6-0H-DA (Waszczak et al., 1984).
The interpretation of the effects of APO are complicated since the VP/SI is extensively
innervated by other dopaminoceptive brain regions (also true for the SNr). Thus, the
effects of a systemically administered, nonselective DA agonist on VP/SI neuronal
activity may reflect the summated stimulation of all dopaminoceptive afferents to this
brain region, as well as the simultaneous activation of the Di and Di receptor subtypes
within the VP/SI.
The results of the third series of experiments demonstrated that DA receptors
within the VP/SI mediated the effects of selective D1 or

Di DA agonists, and that

stimulation of either receptor within this brain region was sufficient to alter the activity
of VP/SI neurons. Furthermore, locally-applied DA often inhibited VP/SI activity,
confirming the results of earlier studies (Napier and Potter, 1989; Napier et al., 199lb).
Likewise, attenuation of these effects by intra-VP/SI application of selective D 1 or

Di

receptor antagonists concur with previous results of systemically administered Di or Di
receptor antagonists (Napier et al., 199lb). Interestingly, the inhibitions induced by
intra-VP/SI application of SKF occurred more often, and to a greater extent than those
induced by DA. Since intra-VP/SI application of QUIN often excited VP/SI neurons,
the effects of DA may reflect the summation of opposing activation of Di and D2
receptors within this brain region. However, most of the VP/SI neurons that were
tested with both D1 and Di DA agonists were sensitive to only one agonist, suggesting
that the opposing effects of D1 and Di receptor activation may be mediated by different
neurons.
Stimulation of the VTAfSNc also evoked inhibitory and excitatory responses of
VP/SI neurons. Most of the VP/SI neurons that were tested with VTAfSNc stimulation
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and intra-VP/SI microiontophoretic application of DA demonstrated similar effects to
both treatments. This suggests that endogenous release of DA within the VP/SI may
mediate the VTA/SNc-evoked VP/SI responses. Likewise, the effects of stimulating the
VTA/SNc were attenuated by either application of SCH or SUL within the VP/SI,
verifying that the effects are DA-mediated, and indicating that activation of the either
receptor subtype is sufficient for inducing these changes in VP/SI neuronal activity.
Thus, 1) separate D1 or Di receptor stimulation is sufficient to alter the activity of VP/SI
neurons, 2) D1 receptor activation is more effective than Di receptor activation within
the VP/SI, and, 3) since both subtypes are present within the VP/SI, DA can mediate its
effects on the VP/SI through either receptor subtype.

Modulatory Effects of DA
Current reviews suggest that the role of DA within the brain may be to act as a
neuromodulator, regulating and integrating functions of the neuronal systems that
receive dopaminergic innervation (Bunney et al., 1991; Graybiel, 1990; Le Moal and
Simon, 1991; Smith and Bolam, 1990). This neuromodulatory role of DA takes into
account the variety of behavioral responses attributed to activation or inactivation of the
DA system (Le Moal and Simon, 1991), and suggests that DA acts as a gain-control
system, adjusting the amount of influence that each brain region has on the final
behavioral output (Graybiel, 1990; Le Moal and Simon, 1991). Moreover, studies of
DA replacement in animals with DA-depleting lesions and humans suffering from
Parkinson's disease support a neuromodulatory role for DA. Loss of dopaminergic
neurons in Parkinson's disease or DA-depleting lesions results in the impaired ability of
initiate movement. However, the anatomical substrate for motoric behavior is not
eliminated by dopaminergic cell loss, since these behaviors are restored by the
exogenous replacement of DA (Le Moal and Simon, 1991). Thus, it appears that the
121

normal function of DA is to enable the initation of appropriate movement to
environmental or internal stimuli.
Similarly, both intracellular and extracellular recording studies support the
neuromodulatory actions of DA. Intracellular recording studies in the STR indicate that
DA acts as a neuromodulator, attenuating both excitatory (glutamate-induced) and
inhibitory (GABA-induced) effects on the activity of STR neurons (Bernardi et al.,
1984; Mercuri et al., 1985). DA acts as a functional antagonist of excitatory STR
neurons evoked by local stimulation of the STR by activating Di receptors, which
induces a depressant action on the postsynaptic membrane, and limits the excitability of
STR neurons to a depolarizing event (Calabresi et al., 1987, 1988). Prior stimulation of
midbrain dopaminergic regions attenuates the extracellularly recorded: 1) excitatory
STR responses to cortical stimulation (Hirata et al., 1984), 2) excitatory NA responses
to stimulation of the hippocampus, AMN (Yang and Mogenson, 1984; Yim and
Mogenson, 1982) or parafascicular nucleus of the thalamus (Akaike et al., 1984), 3)
inhibitory GP responses to cortical stimulation (Hirata and Mogenson, 1984 ), and 4)
excitatory (Chapter V) and inhibitory (Yim and Mogenson, 1983; Chapter V) VP/SI
responses to AMN stimulation.
The results from the third series of experiments (Chapter V) confirmed that the
convergence of midbrain dopaminergic and AMN inputs within the VP/SI allowed for
dopaminergic modulation of VP/SI responses evoked by electrical stimulation of this
AMN input. Electrical stimulation of the VTA/SNc, which presumably involves the
release of endogenous DA, or exogenously-applied DA within the VP/SI attenuated the
VP/SI responses to AMN stimulation.

Historically, the effects of DA on the

spontaneous and AMN-evoked activity of the VP/SI are thought to occur at the level of
the NA (Mogenson and Yang, 1991; Yang and Mogenson, 1989; Yim and Mogenson,
1983). The present results suggest that the VP/SI is also a site of the modulatory effects
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of DA on the monosynapticalJy- and polysynaptically-mediated VP/SI responses to

AMN stimulation. Furthermore, the VP/SI long latency inhibitory responses to AMN
stimulation appeared to be more sensitive to DA than the AMN-evoked excitatory
responses of VP/SI neurons, suggesting that certain limbic information from the AMN
which excites the VP/SI may bypass DA modulation. Thus, future studies should
investigate whether the modulatory role of DA is selective for certain alterations of
VP/SI neuronal activity (i.e., are other inhibitory influences on VP/SI activity, such as
those from the NA, also attenuated more readily by DA).

Potential Si2nificance of DA within the VP/SI
Locomotor Behavior. Studies indicate that the VP/SI, with its innervation to
the pedunculopontine nucleus (Swanson et al., 1984), is involved in the initiation of
locomotor behavior (Mogenson and Nielson, 1983, 1984; Mogenson et al., 1985;
Mogenson and Wu, 1986; Mogenson and Yang, 1991). The input from the NA to the
VP/SI, and the dopaminergic modulation of this NA afferent system, has been similarly
implicated in the induction of locomotor activity (Austin and Kalivas, 1991; Jones and
Mogenson, 1980; Kalivas et al., 1991; Mogenson and Nielson, 1983; Mogenson and
Yang, 1991). Anatomical and electrophysiological studies concur that the VP/SI is
dopaminoceptive and its neuronal activity can be altered by DA (Napier et al., 1991a).
The present studies confirmed that electrical stimulation of the ascending dopaminergic
projection from the VTAfSNc evoked responses in VP/SI neurons. Recent evidence
suggests the VP/SI is also a site for DA-mediated activation of locomotor behavior
(Napier, 1992b; Napier and Chrobak, 1992). Thus, DA-mediated changes in the
activity (and thus, the output) of VP/SI neurons may be reflected by an initiation of
locomotor behavior.
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Reward. Arousal and Dru2 Reinforcement.

The VP/SI may also be

involved with the increased arousal due to reinforced stimuli since changes in activity of
many of these neurons occur in response to rewards and reward-associated stimuli (for
review see, Richardson and DeLong, 1991). DeLong (1971) observed that some SI
neurons in rhesus monkeys exhibit consistent alterations in discharge when a juice
reward is delivered. These neurons also respond to the sight and taste of food, as well
as to the satiety level of the animal (Rolls et al., 1980). VP/SI neurons are highly
responsive to events that precede a reward or movements made to obtain a reward
(Richardson and DeLong, 1986). However, the VP/SI neurons that respond to
appetitive stimuli also respond to aversive stimuli, suggesting that this region may be
influenced by the arousing nature, and the behavioral significance, of these stimuli
(Richardson and DeLong, 1991). Furthermore, the VP/SI is also an important site for
mediating the reinforcing effects of cocaine (Hubner and Koob, 1990; Robledo and
Koob, 1992) and heroin (Hubner and Koob, 1990). Although studies indicate that
dopaminergic transmission within the NA contributes to some aspects of drug selfadministration (Koob et al., 1991), the contribution of DA within the VP/SI to
motivated behavior and drug reinforcement should also be investigated. Since
motivated behaviors and the reinforcing properties of drugs are both processed through
the VP/SI in the rat, the circuitry involved with the former may assist in the discovery of
the anatomical substrate for drug dependence in humans (Koob et al., 1991).

VP/SI Choliner2ic Neurons. Previous electrophysiological studies have
demonstrated that the VP/SI provides a substantial cholinergic innervation of the cortex
(Aston-Jones et al., 1984, 1985; Lamour et al., 1986; Reiner et al., 1987) and that these
cholinergic neurons exhibit heterogeneous physiological properties (Aston-Jones et al.,
1984, 1985; Reiner et al., 1987). Cholinergic neurons that comprise the VP/SI cortical
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projection display a variety of impulse amplitudes and waveforms, and have discharge
rates of 0-40 Hz (Aston-Jones et al., 1984). Since the VP/SI neurons studied in this
dissertation have similar characteristics to these cholinergic neurons, and the recording
sites overlap with those of the previous studies, it is likely that the present data included
a portion of these VP/SI cholinergic neurons.

Preliminary intracellular

electrophysiology studies of VP/SI neurons in an in vitro slice preparation (Maslowski

et al., 1991) al so suggest that some VP/SI neurons may be cholinergic since they
displayed similar characteristics to septum/diagonal band cholinergic neurons (Griffith
and Matthews, 1986; Griffith et al., 1991 ).
The VP/SI may influence cognitive function through its cholinergic projection to
the cortex. Electrical stimulation of the VP/SI has been shown to affect the firing rate of
cortical neurons (Rigdon and Pirch, 1984), and kainic acid-induced lesions in the VP/SI
result in a 603 reduction in cortical ChAT activity (Pirch et al., 1985). In addition,
frontal cortex neurons in unanesthetized rats trained to associate a light cue with medial
forebrain bundle stimulation exhibit cue-elicited rate changes which are attenuated by
kainic acid-induced lesions of VP/SI (Pirch et al., 1986, 1991). These conditioned
responses of the frontal cortex are associated with cognitive processes (Pirch et al.,
1985). Amphetamine produces a dose related depression of these potentials that is
subsequently blocked by haloperidol (Pirch and Corbus, 1983).

Systemic

administration of QUIN mimics the effects of amphetamine whereas SKF has the
opposite effect on the response of cortical neurons to the conditioning stimulus (Pirch et

al., 1988). Cognitive processes associated with cue-elicited changes in cortical activity
involve the dopaminergic modulation of VP/SI cholinergic neurons (Pirch and Corbus,
1983; Pirch et al., 1988), even though working memory tested on a 12 arm radial maze
was not altered by intra VP/SI injections of DA (Napier and Chrobak, 1992). The
effects of dopaminergic agents within the VP/SI on the conditioned potentials, and the
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assessment of cognitive behaviors with testing paradigms other than the radial arm maze
requires further investigation.
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future Directions of VP/SI Research
Potential experiments may inc1ude identifying VP/SI neurons through their
efferent projection by antidromic stimulation, and determining the effects of
dopaminergic agents within the VP/SI on these antidromical1y-activated VP/SI neurons.
Similarly, the VP/SI responses to orthodromic stimulation of the VTA/SNc (which
presumably releases endogenous DA) can be assessed for VP/SI neurons whose
efferent targets have been identified. Previous studies have demonstrated that VP/SI
neurons projecting to the pedunculopontine nucleus are differentially affected by AMN
or hippocampal stimulation (Tsai et al., 1989). Thus, differences in the effects of DA
may be revealed for VP/SI neurons which project to the pedunculopontine nuc1eus
versus those innervating the AMN and cortex.
Another electrophysiological technique that may assist in characterizing the
different types of VP/SI neurons is intracellular recordings of VP/SI slices. As
described above, preliminary studies indicated that at least three different cell type exist
in this region (Maslowski et al., 1991), and that one type exhibits similar characteristics
to cholinergic neurons of the medial nucleus and the nucleus of the diagonal band
(Griffith and Matthews, 1986; Griffith et al., 1991). Future studies using intracellular
fluorescent dyes in combination with ChA T staining may confirm these VP/SI neurons
as cholinergic. In addition, inactivation of afferent input to the VP/SI, which can be
done readily in this in vitro preparation, can determine the direct effects of dopaminergic
agents on VP/SI neurons and may explain the multifarious effects of DA in vivo.

The VP/SI in Alzheimer's Disease and Parkinson's Disease
This dissertation involved the study of normal brain activity as a basis for the
initial understanding of the clinical manifestations of Alzheimer's disease and
Parkinson's disease.

Anatomical studies have demonstrated that the midbrain
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dopaminergic system, which is primarily involved in Parkinson's disease, projects to
the cholinergic and non-cholinergic neurons of the VP/SI (Zaborszky et al., 1991). The
results presented in this dissertation indicate that stimulation of the VTNSNc alters the
activity of VP/SI neurons. Since location of the cholinergic and non-cholinergic neurons
within the VP/SI overlap, the VP/SI may be an integrative site for dopaminergic
afferents with both VP/SI cholinergic and non-cholinergic neurons. Thus, degeneration
of dopaminergic afferents to the VP/SI in Parkinson's disease may seriously affect the
normal neuronal activity of the VP/SI. In addition, loss of VP/SI cholinergic neurons in
Alzheimer's disease (l..ehericy et al., 1991) may result in transneuronal degeneration of
dopaminergic neurons. The association of the VP/SI with motoric and cognitive
behavior suggests that altered activity of this brain region due to disease or drug
intervention may result in aberrant movement and thought processes.
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